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It is widely held that for an HIV-1 vaccine to provide sterilizing immunity, it would need 
to elicit broadly neutralizing antibodies (bnAbs).  However, factors underlying the 
development of these antibodies are not clear.  There is evidence to suggest that in 
some individuals who develop bnAbs, the development of breadth is influenced by the 
co-evolution of the transmitted/founder (t/f) virus and earlier strain-specific neutralizing 
antibody (ssnAb) responses.  Here we characterized the viral evolution, ssnAb and 
bnAbs responses in CAP292, an HIV-1 infected woman who developed bnAb 
responses from one year post infection.  
We used single genome amplification (SGA) to characterize viral evolution at four time 
points: at acute infection; after the development of strain-specific neutralizing 
responses; at the first detection of the broadly neutralizing antibody response; and 
lastly, at the peak of the broad response.  We identified the t/f virus, and generated 
chimeric viruses from this to determine the targets of the ssnAb responses.  A panel 
of site-directed mutant viruses were used to map the specificity of the bnAb responses.  
Our data indicated that infection was most likely founded by a single virus and that the 
first wave of ssnAbs emerged at 14 weeks post infection (w.p.i), targeting the V1V2 
loop of Envelope (Env).  A second wave of ssnAbs, possibly targeting the C3V4 region, 
emerged by 30 w.p.i.  Two distinct viral clusters were detected by the time the bnAb 
response peaked, suggesting the presence of distinct escape pathways.  Mapping of 
the bnAb specificities indicated that CAP292 produced PGT128-like bnAb responses 
targeted toward the 332 glycan.   
These data illustrate that an early ssnAb response emerged towards the C3V4 region, 
with a later bnAb response possibly targeting the C3 glycan at position 332. Further 
vi 
work is required to confirm the target of the bnAbs and determine whether there was a 
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1 Literature review 
1.1 Introduction 
Since its discovery in 1983, the HIV-1 epidemic has expanded with 36.9 million people 
living with HIV-1 in 2014 1.  While there are several HIV-1 subtypes and circulating 
recombinant forms, subtype C makes up 56% of the pandemic and is responsible for 
the overwhelming majority of infections in South Africa 2.  About 18% of the South 
African adult population (15-49 years old) are living with HIV-1.  Although prevalence 
has stabilized, the global 2 million new infections in 2014 indicate that the epidemic is 
far from over 1.   
It is well established that antiretroviral drugs (ARVs) prevent mother to child HIV-1 
transmission 3 4, and more recently treatment as prevention (TasP) is being used as 
an available intervention method to reduce sexual transmission of HIV-1.  There is 
ample evidence to support TasP in HIV-1 negative individuals:  firstly, ARVs when used 
as pre-exposure prophylaxis reduce HIV-1 acquisition rates in men who have sex with 
men (MSM) 5 and in discordant heterosexual couples 6 7 8 9 10 11 12; and in one study 
topical application of ARV-based microbicides reduced HIV-1 acquisition in women 13.  
The use of ARV-based microbicides in HIV-1 prevention has not been reproduced in 
other clinical trials 14 15.  Treatment of HIV-1 infected individuals can reduce 
transmission by 96% 6 and the global benefit of TasP is that the treatment of a large 
proportion of HIV-1 infected individuals has the potential to reduce the HIV-1 
‘community viral load’ and subsequently reduce the chance of HIV-1 transmission at a 
population level 16 17 18.   
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However, TasP has limitations that may prevent its full effectiveness: (i) access to 
treatment is not universal; for instance, in 2013 only 2.6 million of the 6.8 million were 
receiving treatment in South Africa 19, (ii) the scale of the required roll-out for supply of 
medications has a negative financial implication; especially for the economies of 
developing countries 20 21, (iii) there may be low adherence to medication due to 
adverse drug reactions , socio-economic status, social stigma and other psychosocial 
conditions (e.g. drug and alcohol use, depressive symptoms, anxiety symptoms) 22 23 
24 25, (iv) ultimately low adherence may lead to drug resistance 26, which is in itself a 
limitation of TasP. 
Vaccines are the most effective way to control viral pandemics 27 and offer a solution 
to the limitations of TasP.  Through reducing number of new infections and providing 
herd immunity, vaccines can ultimately lead to the eradication of the HIV-1 epidemic.   
 
1.2 HIV-1 vaccine trials 
Although there is no effective vaccine against HIV-1 acquisition, four vaccine concepts 
have been tested in large proof of concept (Phase 2b) or efficacy trials (Phase 3) 
including: protein subunit proteins (VAX003 and VAX004); Ad5 vaccine vectors 
(HVTN502 and HVTN503), poxvirus vector prime protein boost (RV144); and DNA 
prime Ad5 vector boost approaches (HVTN 505).  The trial dates are shown in Figure 
1.1.   
The first Phase 3 efficacy trials were conducted between 1998 and 2003.  The VAX004 
and VAX003 trials investigated the use of HIV-1 subunit proteins to elicit a neutralizing 
antibody response to prevent HIV-1 infection.  VAX004 used a recombinant gp120 
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from subtype B viruses, while VAX003 used subunits from subtypes B and E.  These 
trials were conducted in an MSM population and heterosexual women at high risk of 
HIV-1 infection.  A weak neutralizing antibody response was mounted in both trials, 
which was only effective against highly neutralization sensitive viruses and did not 
protect against infection.  Therefore, these vaccines showed no efficacy 28 29.   
Between 2004 and 2007, the second concept tested was the induction of T cell-
mediated responses to reduce viral load and delay clinical disease progression.  The 
STEP/HVTN502 and Phambili/HVTN503 Phase 2b trials tested this concept by using 
a replication-deficient vector Adenovirus serotype 5 (Ad5) encoding HIV-1 subtype B 
gag, nef and pol genes 30.  STEP was conducted largely in a population of MSM from 
North America, South America and Australia and included high-risk heterosexual men 
and women from the Caribbean.  Phambili was conducted in South Africa in a 
heterosexual population.  The lack of vaccine efficacy resulted in termination of both 
studies.  Of concern was the finding that HIV-1 susceptibility was increased in men 
who had pre-existing immunity to Ad5 and were uncircumcised in the STEP trial.  In 
both trials, the vaccine failed to lower viral load and delay disease progression in those 
who became infected 30 31.  Although the vaccine elicited T-cell responses, they were 
narrow and only targeted one to three epitopes 32.   
A third concept tested aimed to elicit both T cell responses and neutralizing antibodies 
was and was evaluated in the RV144 trial in Thailand 33.  This trial was conducted 
using the prime-boost strategy.  The vaccine candidate prime was a canarypox vector 
containing HIV-1 subtype B gag, pol and env (envelope) genes.  The boost contained 
a recombinant of gp120 containing subunits from HIV-1 subtypes B and E.  Although 
the vaccine had no effect on the peak viremia after infection, HIV-1 acquisition was 
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reduced by 31% 33.  A correlate of risk analysis showed the vaccine recipients who did 
not acquire infection had V2 loop Env binding antibodies 34.  This suggests that 
inducing anti-HIV antibodies targeting the V1V2 loops may be important in preventing 
infection. 
Lastly, the HVTN505 Phase 2b trial was conducted between 2009 and 2013 35.  The 
trial was conducted in MSM or transgendered women who have sex with men in the 
United States of America (USA).  A prime-boost strategy to elicit both T cell-mediated 
responses and neutralizing antibodies was employed.  The vaccine regimen contained 
a prime that was made up of a DNA plasmid containing env from subtype A, B and C, 
and gag; pol and nef genes from subtype B.  The boost comprised a recombinant 
Adenovirus serotype 5 (Ad5) vector containing env from subtype A ,B and C, as well 
as gag and pol from subtype B 35. Similarly, the vaccine failed to protect against 
acquisition of infection and did not lower viral load post acquisition. 
 
Figure 1.1. HIV-1 Human Vaccine Clinical Trials.  An illustration of four 
concepts tested in five human clinical trials conducted to date.  The trial name, 
vaccine antigens and the year of initiation and termination of the trials are 
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indicated.  The HVTN505 Trial was initiated in 2009, and was meant to progress 
into 2015.  This was halted (black bar) in 2013 (Figure from Esparza et al. 36).   
 
1.3 Why neutralizing antibodies are important 
Neutralizing antibodies (nAbs) are a known correlate of protection in most licensed 
vaccines (reviewed by Plotkin 27) and provide sterilizing immunity against SIV in non-
human primates 37.  nAbs lag behind the high rate of mutation and immune escape by 
the virus rendering them ineffective against contemporaneous viruses (reviewed by 
Mascola 38).  Moreover, the high level of viral diversity results in early antibodies that 
are only able to target a portion of the viral population that elicited them, and are thus 
strain-specific.  Antibodies that are able to neutralize HIV from different individuals are 
known as broadly neutralizing antibodies (bnAbs) and have been isolated from 
chronically infected individuals.  Studies have shown that passive transfer of bnAbs in 
nonhuman primates protects against infection 39 37 40.  Additionally, administration of a 
cocktail of these antibodies suppresses viral replication in rhesus monkey chronically 
infected with SHIV (an SIV and HIV-1 chimeric virus) depending on the viral load during 
the time of administering the antibodies 41.  To date no vaccine has been able to elicit 
bnAbs.  Current research is focused on elicitation of broadly neutralizing antibodies 
through vaccination, via a pathway that mimics natural infection (reviewed later) in the 
hope that this will prevent HIV-1 infection in vaccinees.   
 
1.4 HIV-1 envelope architecture 
To better understand the interaction between antibodies and the virus, it is essential to 
understand the architecture of the HIV-1 envelope protein (Env), as it is the target for 
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neutralizing antibodies.  Env, comprises heterodimers of non-covalently bound surface 
gp120 and transmembrane gp41 (gp: glycoprotein).  The gp41 is anchored to the 
membrane by a 7-stranded-β–sandwich 42.  The heterodimers are arranged as trimers 
also known as ‘spikes’ on the viral membrane 43.   
The gp120 is made up of a highly glycosylated outer domain, bridging sheet and an 
inner domain (Figure 1.2).  The outer domain is made up of five variable loops -V1, 
V2, V3, V4 and V5; with the more conserved constant domains (C1, C2, C3, C4 and 
C5) make up the inner domain 44 45.  Three of the variable loops, V1, V2, V3 form an 
association domain at the apex of the spike that stabilizes the conformation of the 
envelope protein (Env).  The amino acid residues necessary for the binding of the 
infection co-receptor are found in V3 and the bridging sheet, linking V1V2 with V3.  The 
role of the V4 and V5 have not been clearly defined, but may be targets for neutralizing 
antibodies and/or mask regions of antibody sensitivity.  The C2, C3 and C4 domains 
form a hydrophobic cavity that makes up the CD4-binding site 46.  The three monomers 
of gp41 form a mushroom-like shape at the base of gp120.  Gp41 is made up of an 
ectodomain on the N-terminus and a transmembrane domain on the C-terminus.  The 
ectodomain contains two heptad repeat regions (HR1 and HR2), membrane-proximal 
external region (MPER) and a hydrophobic fusion peptide.  All components are 




Figure 1.2. Architecture of HIV-1 Envelope.  The core 
gp120 is shown in yellow, the V1V2 in orange and V3 in red.  
The components of gp41 are shown in different shades of 
green. A. Side view of the HIV trimer.  One of the three 
protomers is shown in colour, while the other two are shown 
as a gray mash.  Glycans are shown as spheres.  B. Top 
view of HIV trimer.  The components of gp120 are indicated 





1.5 Envelope mediates entry into target cells 
The HIV-1 Env spike transitions between three distinct conformations to allow viral 
entry into the host cell- pre-fusion, intermediate and post-fusion.  The pre-fusion, also 
known as ‘native’ Env conformation is described above.  Here, we review the 
conformational changes that occur, leading to the entry of viral genetic material into 
the host targeted cells (Figure 1.3).   
The first conformational changes occur upon binding of CD4, to the viral CD4-binding 
site located in the hydrophobic cavity formed in the gp120 inner domain.  The gp120 
bridging sheet undergoes changes to become a 4-stranded-β-sheet.  The V3 
dissociates from the V1V2 loop and extends away from the spike, toward the target 
cell membrane.  Both the bridging sheet and the V3 orientate towards the cellular 
membrane to initiate co-receptor binding.  A cavity is then formed wherein the cellular 
co-receptor (CCR5) binds 47 48 49.  The major co-receptors for HIV-1 binding are 
chemokine receptors CCR5 and CXCR4.  The bridging sheet comes into contact with 
the co-receptor followed by the V3 loop 50 51.  This induces conformational changes in 
gp41, leading to the formation of a six-helical bundle by rearrangement of HR1 and 
HR2.  This brings the cellular and viral membrane into close proximity.  A fusion pore 





Figure 1.3. Viral entry into target cells.  HIV-1 first initiates contact with 
the target cell by binding to the α4β7 integrin.  The CD4 binding site on the 
HIV-1 gp120 then binds to CD4 expressed on the target cell.  This binding 
results in conformational changes in the gp120 resulting in exposure of the 
V3 co-receptor binding site.  The V3 loop interacts with the CCR5 co-
receptor on the target cell.  Following this engagement with the co-receptor, 
the gp120 undergoes further conformational changes which facilitate the 
insertion of the gp41 fusion peptide into the host membrane.  HR1 and HR2 
consequently interact to form a six-helix bundle which brings the viral and 
host membranes into close proximity.  A fusion pore is formed allowing entry 
of the HIV-1 capsid into the target cell (Figure from Haqqani & Tilton 54).   
 
Viral entry is the first step of the viral replication cycle.  Described below are the events 
that occur once infection is established and immune responses emerge. 
 
1.6 HIV-1 transmission bottleneck and expansion of transmitted/founder virus. 
Sexual transmission of HIV-1 occurs when either cell free or cell associated virus 
crosses the mucosal epithelium through transcytosis, direct contact with CD4+ T cells 
or migration through intercellular spaces 55 56.  The epithelium acts as a ‘genetic 
bottleneck’, allowing only one, or a few, viral variants through the mucosal barrier to 
establish infection in the new recipient 57 58 59.  About 80% of transmission events that 
result in clinical infection are by a single viral variant, owing to the severity of the 
transmission bottleneck 60 61 62.  In the other 20%, infection is caused by between two 
to five closely related variants 60.  The virus that establishes infection is known as the 
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transmitted/founder virus (t/f) and has properties such as common usage of CCR5 
(co)-receptor to infect target cells, and in HIV-1 subtypes A and C infection, transmitted 
viruses have shorter variable loops and fewer number of potential N-linked 
glycosylation sites (PNLGs), when compared to the variants that emerge later on 
during infection 63 64 65 66 67 68.   
During acute infection, the t/f virus replicates exponentially to reach peak viremia, 
generating genetic derivatives collectively referred to as a quasispecies 69.  The 
quasispecies population in early infection is relatively homogenous, has low diversity, 
a Poisson distribution of hamming distances and a star-like phylogeny typifying 
infection by a single viral variant 60 61.  Deviations from the model would suggest 
multiplicity of infection greater than one.   
Local replication at the site of infection is followed by exponential expansion of the viral 
pool, disseminating virus to the local draining lymph nodes and gut-associated 
lymphoid tissue (GALT).  During this stage, there is high CD4 T cell depletion and 
extensive damage to the lymphoid tissue 70.  This is followed by a sharp decline in viral 
load over the next weeks, to a level of viral load ‘set point’ - a level where viral 




Figure 1.4. Clinical stages of HIV-1 infection.  The red and blue curves 
show the viral load and CD4+ T cell count, respectively, during the different 
stages of HIV-1 infection.  Acute phase stage is marked by an exponential 
increase in viral load, and rapid decline in CD4T+ cell count.  Viral set point 
is reached and maintained in the chronic phase (Figure from 2014.igem.org 
71).   
 
1.7 Immune responses to HIV-1 
This combination of viral replication, dissemination and tissue damage in the early 
stages of infection results in immune activation and the development of HIV-specific 
immune responses (reviewed Appay & Sauce 72) 73.  Here, we review HIV-1 in the 
context of the different immune responses elicited.  We also assess the relevance of 




1.7.1 Innate immune response 
The innate immune response is the first line of defense against infection and thus the 
first response to interact with HIV-1.  Several systems constitute this response: the 
epithelial barrier, complement system, inflammatory cytokines, and phagocytic cells.  
The early immune stimulation results in the activation of these systems.   
The response is characterized by production of various cytokines and chemokines, an 
increase in acute-phase proteins and activation of Natural Killer T (NKT) cells 74.  NKT, 
are expanded during infection and function by killing virally infected cells through the 
production of granzymes.  The production of acute-phase proteins is triggered by the 
release of pro-inflammatory cytokines such as interleukin-1 (IL-1).  Interferons (IFN) 
have antiviral activity and therefore provide a mechanism for control of HIV-1 
replication and has been associated with reduced viral load and rate of disease 
progression 75 76 77 78 79.  Host restriction factors have also shown to play an important 
role in controlling HIV infection including tripartite motif containing protein (TRIMs), and 
cytosine deaminase protease among others 80.   
However, the immune activation does not always have the desired effect.  The cytokine 
storm that results from chronic immune activation, recruits susceptible CD4+ T cells, 
or dendritic cells to site of infection, which may facilitate spread of the virus to 
uninfected cells 74 81.  Chronic immune activation has also been shown to increase 




1.7.2 Adaptive immune responses 
The adaptive immune response is made up of two arms: the cell-mediated and 
antibody immunity. 
 
1.7.2.1 Cell-mediated responses 
The earliest responses shown to have an impact on HIV-1 replication are cytotoxic T-
lymphocyte cell (CTL) (or CD8+ T cells) which arise just days after infection, before 
development of the first antibodies 74 84.  The peak in these responses coincides with 
the decline in viremia, suggesting that CTLs inhibit HIV-1 replication.  The earliest 
targets of the CTLs are the viral proteins Nef and the highly variable Env.  The more 
conserved proteins such as Gag and Pol are targeted at a later stage 84 85.   
Key viral sequence changes that occur as viral load decreases are often associated 
with CTL responses, and are referred to as CTL escape 86 87.  Escape occurs as single 
or multiple amino acid changes in the T-cell receptor, HLA binding site, or processing 
mutations, and render the mutant viruses resistant to CTL cell responses.  Escape 
may, however, result in reduced replicative potential of the virus when occurring in the 
conserved regions (e.g Gag) 88 89.   
Studies in nonhuman primates highlight the importance of CTLs for vaccine 
development.  CTLs reduced viremia in challenged macaques, and depletion of 
CD8+ T cells resulted in increased viral load, showing that CD8+ T cells were 
responsible for limiting viral replication 90 91.  Additionally, a vaccine candidate 
RhCMV provided long-term control of Rhesus macaques and even cleared infection 
in 55% of macaques.  This protection was associated with non-classical SIV-specific 
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CD8+ T cells responses including MHC-II and MHC-E responses, showing the 
impact of the cells on HIV pathogenesis 92.  However, vaccine studies in humans 
have been unsuccessful in proving the effectiveness of these responses, either in 
preventing infection or in reducing viremia after infection was established, as seen in 
the STEP trial 32.  
 
1.7.2.2 Non-neutralizing antibodies 
The first antibodies against HIV-1 proteins are detectable approximately 13 days 
(ranging from 10 -17 days) post infection in all infected individuals (Figure 1.5) and are 
usually non-neutralizing 93 94.  This means that they bind to viral proteins, but do not 
block viral entry into cells.  They recruit other cells of the innate response such as 
phagocytes, and activate the complement system allowing killing of the virus through 
either complement-mediated lysis, opsonisation by phagocytes or antibody-dependent 
cellular cytotoxicity (ADCC) 95.  High levels of ADCC-mediating non-neutralizing 
antibodies (nnAb) are associated with the maintenance of low viral loads in HIV-1 elite 
controllers 96.  Although they may provide clinical benefit, the presence of ADCC-
mediating antibodies during acute infection does not reduce viremia over this phase of 
infection 94.   
However, the RV144 trial showed that binding antibodies targeting the V1V2 loop were 
associated with the 31% efficacy of the vaccine 34.  These antibodies were shown to 
mediate ADCC by targeting conserved regions in V2 97 98.  Additionally, sieve analysis 
of the viral sequences from vaccine compared to placebo breakthrough infections, 
showed that vaccine efficacy was improved when the viral sequences matched the 
sequence of the vaccine env insert at position 169 and did not match at position 181.  
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The vaccine efficacy was 48% when the amino acid residue at 169 was lysine (K), and 
78% when the residue at 181 was not an Isoleucine (I) 99.  A monoclonal antibody 
(CH58) isolated from a vaccine recipient, showed ADCC activity that targeted K169 
100.  These data showed that amino acid residues in the V2 play a role in HIV-1 
susceptibility and that non-neutralizing immune responses to this region were 
associated with reduced risk of infection.  Due to the overall low efficacy of the vaccine, 
some researchers are suggesting that the non-neutralizing response should be 
complemented by neutralizing antibodies, thus forming a synergistic relationship to 
prevent infection 101. 
 
1.7.2.3 Strain-specific neutralizing antibodies 
Neutralizing antibodies prevent infection of cells by binding to regions of the envelope 
trimer important for entry.  The earliest neutralizing antibodies to develop during HIV-
1 infection are known as strain-specific neutralizing antibodies (ssnAbs), and are 
usually detectable approximately 12 weeks after HIV-1 acquisition and may continue 
to emerge throughout the course of infection (Figure 1.5) 102.  These antibodies are 
produced at high titers in subtype C infections 103.  The fact that they are strain-specific 
suggests that they target the variable regions of env.  Several studies have identified 
the V1V2 region as the most common target, followed by and the alpha-2 helix domain 
in the C3 region in subtype C infections 104 105.  The V4 and V5, are also targeted but 
to a lesser extent 104 106.   
Because ssnAbs develop after viremia has peaked and target highly variable epitopes 
of Envelope, their activity is limited to viral variants that elicited their production, i.e. 
viruses circulating at a time preceding their development.  They are therefore 
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ineffective against the currently circulating virus (contemporaneous viral variants) due 
to the rapid rate of viral escape, which is mediated by single or multiple mutations in 
the envelope.  These mutations work by either sterically inhibiting antibody access to 
the epitope, or by directly changing the epitope so that it is no longer recognizable by 
the antibody.  The most well documented mutations are the insertions/deletions 
(indels) that occur in the hypervariable regions.  These indels typically alter the 
structure of the loops, which then masks the epitopes that would be targeted by 




Figure 1.5. Evolution of antibody responses in HIV-1 infection over 
time.  The first detectable antibodies are non-neutralizing and appear within 
days to one month following infection.  Strain-specific, also known as 
autologous neutralizing antibodies emerge around two months post 
infection and may continue to appear all the way into chronic infection and 
disappear as infection proceeds to the AIDS state.  Cross-reactive 
neutralizing antibodies and elite cross-reactive neutralizing antibodies 
appear between one and two years after.  Elite cross-reactive neutralizing 
antibodies develop at about the same time as cross-reactive neutralizing 
antibodies and are also maintained into the AIDS state (Figure from Euler. 




Due to the ability of the virus to evade the ssnAb response, ssnAbs are considered an 
ineffective immune response.  However , some studies have shown that ssnAb can 
limit HIV-1 replication in early infection 108 109 110 111.  CAP88 – a participant in the 
CAPRISA 002 cohort – had viral loads that declined when ssnAbs were able to 
neutralize 50% of the viral population and continued to decline as neutralization titers 
increased 108.  However, viral load rebounded upon the first detection of mutations in 
the viral env that rendered the viruses resistant to neutralization by ssnAb (Figure 1.6).  
Thus demonstrating that control by ssnAbs is transient due to rapid immune escape. 
 
 
Figure 1.6. Neutralization escape following development of the mutant 
viral variants.  Percent neutralization is shown as a green line, the viral 
load as black, wildtype viral load (WT VL) as blue and mutant viral load (Mut 
VL) as red.  WT VL (blue line) declined between 11 and 15 weeks post 
infection (the gray-shaded area) and coincided with the increase in 
neutralization percentage (green line).  At about 15 weeks p.i., The mutant 
viral load (MT VL, red line) emerged at 15 weeks post infection, resulting in 
the rebound of the overall viral load (VL, black line), and further decline in 




1.7.2.4 Broadly cross-neutralizing antibodies 
Broadly cross-reactive neutralizing antibodies (bnAbs) are antibodies that are able to 
neutralize a wide range of HIV-1 variants, including viruses from different subtypes.  
The ability to neutralize a broad range of viruses is known as ‘breadth’.  It has recently 
been shown that about 50% of HIV-1+ people had sera that could neutralize 50% of 
the viruses in the panel used 112 whilst some bnAbs are able to neutralize more than 
80% of viruses.  Generally, they develop between one and three years post infection 
in 20 to 30% of infected individuals 113 114. 
The recent discovery of monoclonal antibodies with exceptional breadth has enabled 
the detailed elucidation of bnAb targets.  There are five classes of bnAbs characterized 
by the regions of envelope they target.  The most common class of bnAbs is those that 
target the V1V2 regions targeted by PG9/16-like antibodies, as is the case for the 
ssnAb targets.  Other targeted regions are: the glycan-dependent epitope in the C3 
region targeted by PGT128-like antibodies; the CD4 binding site targeted by VRC01-
like antibodies; and the membrane-proximal region (MPER) targeted by 4E10-like 
antibodies.  Recently, another bnAbs epitope has been identified at the interface of 
gp120 and gp41, targeted by the monoclonal antibody 8ANC195) (Figure 1.7) 115 116 




Figure 1.7. Broadly neutralizing antibody targets.  Side and Top view of 
the HIV-1 spike made up of gp120 and gp41 (gray).  The broadly 
neutralizing antibody targets are shown in various colours: V1V2 (yellow), 
CD4 binding site (CD4bs, blue), MPER in dark gray, the glycan-dependent 
V3 epitope in green and lastly the epitope at the interface of gp120 and gp41 
shown in purple.  8ANC195 is shown here as a representative of antibodies 
targeting this interface (Figure from Scharf et al. 121).   
 
In addition to other immune response (e.g. cytotoxic T cell response), an effective 
vaccine would likely need to induce broadly neutralizing antibodies.  Although they do 
not have clinical benefit to the individuals in whom they develop 122, bnAbs are shown 
to have therapeutic benefits in humanized mice and nonhuman primates in several 
studies.  These studies show that administration of monoclonal bnAbs alone or in 
combination into SHIV-infected nonhuman primates or HIV-1 infected humanized mice 
reduced viral loads to undetectable levels 123 124 125.  SHIV (a chimeric HIV and SIV 
virus) acquisition was also prevented in macaques who received passive transfer of 
monoclonal antibody before being challenged with SHIV 125 126.  Caskey et al. (2015) 
conducted the first human study where a monoclonal antibody, 3BNC117, was 
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administered in HIV-1+ and HIV-1- individuals 127.  The study does not show whether 
or not infection was prevented in the negative individuals, but they do show that viral 
load was suppressed in the infected individuals who received several doses of the 
3BNC117 monoclonal antibodies. 
 
1.7.2.4.1 Characteristics of broadly neutralizing antibodies  
The studies above highlight the importance of the broadly neutralizing antibody 
responses in HIV-1 prevention and therapy.  The ability to induce bnAb before HIV-1 
exposure has the potential to protect against infection in humans, as seen in nonhuman 
primates.  However, these antibodies have complex characteristics and maturation 
pathways, which contribute to the difficultly of designing an immunogen that would elicit 
these antibodies through vaccination.  In addition, these characteristics vary according 
to the class of bnAb:  The CD4-binding antibody class typically shows a high somatic 
mutation rate in the antibody heavy chain complementarity determining regions 2 
(HCDR2) 128.  This allows for an interaction between the antibody and the epitope that 
mimics CD4 binding 129 130 131.  The antibodies that recognize the glycan-dependent 
epitopes in the V1V2 class have comparatively long HCDR3 loops, with high rates of 
somatic mutation.  This length of the HCDR3 loops allows penetration of the glycan 
shield and access to the epitope.  The MPER and N332 glycan in C3 classes also have 
long HCDR3 and high levels of somatic mutation 132.   
It is clear that bnAb classes have unique features that separate them from other 
neutralizing antibodies.  A vaccine aiming to elicit one or more of these antibodies may 





1.7.2.4.2 Developmental pathway of broadly neutralizing antibodies 
To understand how bnAbs develop, it is important to consider the events that occurred 
prior to their development, i.e. the interactive evolution of the strain-specific response 
and the transmitted virus.  Two separate studies, Liao et al. 133 and Doria-Rose et al. 
134 showed that strain-specific neutralizing antibodies drove early viral escape, which 
in turn facilitated the diversification of an antibody lineage towards the development of 
breadth bnAb.   
In the Liao et al. study 133, donor CH505 was followed from acute infection to more 
than 3 years post infection – that is after development of the bnAb response.  CH103, 
the antibody lineage that conferred broad neutralization, targeted the CD4 binding site.  
The emergence of the CH103 germline was dated to 4 weeks post infection (w.p.i), 
whilst the bnAb response emerged between 42 and 92 w.p.i.  The earliest mutations 
in env coincided with the development of the first neutralizing antibodies.  The t/f virus 
bound well to the antibody germline sequence known as the unmutated common 
ancestor (UCA), but heterologous envelope proteins could not bind UCA.  This 
suggested that the antibody-binding was highly strain-specific.  Conversely, late 
intermediate antibodies of this antibody lineage could not bind to transmitted virus, but 
could bind heterologous Env, suggesting that these antibodies had undergone somatic 
hypermutation to allow neutralization of the evolved Env. 
In the Doria-Rose et al study 134, the development of bnAbs was investigated in 
participant CAP256 of the CAPRISA002 cohort.  This donor was initially infected with 
one virus, and superinfected with a second strain 15 weeks later.  In this individual, the 
CAP256-VRC26 bnAb clonal lineage targeted the V1V2 region.  Their data showed 
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that the CAP256-VRC26 antibody lineage neutralized the superinfecting virus, but not 
the primary infecting virus.  This suggested that the superinfecting virus primed the 
initial B cell response.  Mutations in env were detected in the superinfecting virus at 
the time of the emergence of the first CAP256-VRC26 antibody response, suggesting 
the antibody responses drove escape in the superinfecting virus 135.   
What these two studies show is that strain-specific neutralizing antibodies target a very 
narrow range of envelope variants.  The development of this response drives viral 
diversification in the targeted epitope towards viral variants that are resistant to 
neutralization.  Neutralizing antibodies, primed by the founder virus, undergo affinity 
maturation which, in some cases, leads to antibody daughter lineages that are better 
able neutralize a broader range of viral variants (Figure 1.8).  To facilitate vaccine 
designs that will induce bnAb responses, it is important to understand the relationship 
between ssnAbs and viral evolution in the development of bnAbs. 
Figure 1.8. Development of broadly neutralizing antibodies from 
strain-specific neutralizing antibodies.  Strain-specific neutralizing 
antibodies target single epitope.  The epitope evolves by accumulation of 
mutations, resulting in various escape viral variants.  At the same time, the 
antibody undergoes evolution.  Escape variants and neutralization breadth 




To characterize the early strain-specific neutralizing antibody response; and resulting 
viral evolution; and to determine the relationship between epitopes targeted between 
strain specific neutralizing antibody and the later broad neutralizing response in an 
individual who subsequently developed broadly cross-neutralizing antibodies.   
Rationale:  The complex characteristics of broadly neutralizing antibodies suggest that 
it will be difficult to elicit these responses by vaccination.  One school of thought is that 
viral evolution drives the development of breadth, and that this could be recapitulated 
in humans through sequential vaccination with viral variants responsible for eliciting 
breadth 136 133137 138 134.  This project will characterize viral variants and strain-specific 
and broadly neutralizing antibody targets in early infection in CAP292, a participant of 
the CAPRISA004 trial, who developed neutralization breadth at one year post infection.  
The project forms part of a larger study that will define virus-host co-evolution over 
three years in CAP292 with the aim to define viral and host factors conducive to the 
development of BCN antibodies in natural infection.  The overall purpose is to design 
cocktail vaccines that recapitulate epitope diversification in natural infection (“Broad 
Neutralizing HIV-1 Antibodies, Adjuvants and Immunogens”, Principal Investigator P. 





• To determine the multiplicty of infection and identify the transmitted founder 
virus(es) 
• To determine the kinetics of the early strain specific neutralizing antibody 
responses in a broad neutralizer, CAP292. 
• To identify sites under selection pressure from strain-specific neutralizing 
antibodies and to map the targets for the early neutralizing response. 
• To screen a panel of well-characterised bnAb escape variants, to identify 
broadly neutralizing antibody specificities.  
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2  Methods and materials 
2.1 Selection of study subject and plasma samples 
CAP292, a participant from the CAPRISA (Centre for AIDS Program of Research in 
South Africa) 004 cohort, was selected for this study.  The CAPRISA004 cohort was 
established for a trial to determine the effectiveness of a tenofovir microbicide gel in 
preventing HIV-1 infection in women 13.  HIV-1 infection date was determined as the 
midpoint between the last antibody-negative test and the first antibody-positive test, 
based on two HIV-1 rapid antibody tests (namely, ‘Determine HIV1/2’ [Abbot 
Laboratories, Illinois, USA] and ‘UniGold Recombigen® HIV test’].  HIV diagnosis was 
confirmed by RNA PCR and laboratory enzyme linked immunosorbent assay (ELISA).  
Following diagnosis, the CD4+ T cell count and viral load were determined using the 
TruCOUNT method (BD Biosciences, San Jose, USA) 139.   
Plasma samples were collected weekly for 3 weeks, biweekly for 3 months and 
quarterly thereafter.  Plasma samples for this study were selected from several time 
points spanning the first year of infection (6, 30, 58 w.p.i), as well as a three year time 
point (186 weeks post infection).  These samples were made available by CAPRISA 
(Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, and 
University of KwaZulu-Natal).  This study was approved by the University of Cape 




2.2 Extraction of viral RNA 
HIV-1 RNA was extracted using the QIAGEN QIAamp ® Viral RNA Mini Kit (Qiagen, 
Valencia, CA) following the manufacturer’s instruction.  This method is based on pH 
and chaotropic salt dependent binding of nucleic acids to silica beads.  Briefly, RNA 
was extracted from 140-200 µl plasma (for high and low viral load, respectively).  
Samples with less than 100 000 viral copies/ml were considered as low viral load when 
determining plasma volume for extraction.  The extracted RNA was eluted in 50 µl AVE 
Elution buffer.   
 
2.3 Synthesis of complementary DNA (cDNA) 
The synthesis of the complementary DNA (cDNA) was carried using the SuperScript™ 
III Reverse Transcriptase System (Invitrogen Life Technologies, Carlsbad, CA) 
according to the manufacturer’s instructions, using 50 µl RNA, 0.25 µM Oligo-dT primer 
(Invitrogen) and 0.5 mM of each dNTP (Invitrogen), made up to 65 µl with DEPC-
treated water (Sigma-Aldrich, St Louis, MO).  This mixture was heated at 65 ⁰C for 5 
minutes to denature RNA secondary structure and allow primer binding.  To this 
reaction, the second reaction mix containing 10 units of Superscript III Reverse 
Transcriptase, 1X First strand buffer, 5 mM of Dithiothreitol (DTT) (Invitrogen) and 2 
mM RNaseOUT (Invitrogen), made up to 35 µl with DEPC-treated water (Sigma-
Aldrich) was added and the reaction incubated at 45 ºC for 2 hours, followed by enzyme 
inactivation at 70 ºC for 15 min.  RNA was removed from the sample, to prevent RNA 
from interfering with subsequent amplification steps, by the addition of RNase H (1 




2.4 Single genome amplification of HIV-1 gp160 
Single genome amplification (SGA) allows PCR amplification from a single DNA 
template molecule 61.  Given the diversity of HIV-1 quasispecies in samples at any 
given time, this precludes Taq induced errors such as recombination, which occurs 
when Taq switches from one template to one that is genetically different.  Moreover, it 
reduces the chance of sample bias where re-amplification of one template is favoured.  
After amplification, a yield of less than 30% positive reactions indicates that 
amplification is highly likely to have occurred from one template in 80% of these 
positive reactions 61.  This method allows accurate molecular characterization of 
circulating viral strains. 
Here, SGA of HIV-1 gp160 was done as nested PCR, with amplifications carried out in 
a 96 well PCR plate (WhiteHead Scientific).  The first round PCR reaction contained 
1X Platinum® Taq High-Fidelity polymerase buffer (Invitrogen), 2 mM MgSO4, 0.2 mM 
of each dNTP (Invitrogen), 0.2 µM Vif1 primer (5’- 
GGGTTTATTACAGGGACAGCAGAG -3’; HXB2 nt 4900 - 4923), 0.2 µM OFM19 
primer (5’-GCACTCAAGGCAAGCTTTATTGAGGCTTA -3’; HXB2 nt 9604-9632) 
(WhiteHead Scientific; Appendix A), 0.025 units Platinum® Taq High Fidelity 
polymerase (Invitrogen) and 1 µl of the cDNA, made up to 20 µl with distilled H2O.  The 
cycling conditions were set at: 94 ºC for 2min, 35 cycles of 94 ºC for 15 seconds (s), 
58 ºC for 30 s, and 68ºC for 4 min and a final extension step of 68 ºC for 10 min.  The 
nested PCR was carried out as above with the following exceptions: first round PCR 
product (1µl) was used as the template and 0.2 µM of primers ENV1A-Rx (5’- 
CACCGGCTTAGGCATCTCCTATAGCAGGAAGAA-3’) and EnvN (5’- 
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TTGCCAATCAAGGAAGTAGCCTTGTGT -3‘) were used, while the number of cycles 
was increased to 45. 
 
2.5 Generation of chimeras using the overlap extension PCR and mega primer 
PCR strategies 
HIV-1 Env chimeras were generated by introduction of the V1V2 and C3V4 regions 
from CAP292 into the neutralization resistant Env backbone from CAP239, for 
mapping of the strain-specific neutralizing antibody response.  To map regions 
involved in escape at different time points, the V1V2 and C3V4 regions of the CAP292 
t/f virus were introduced into the envelope of viruses from 30 and 58 w.p.i.  These 
chimeras were generated using two strategies: overlap extension PCR 140 and the 
modified version of the overlap extension PCR 141, here referred to as the ‘mega primer’ 
strategy.   
 
2.5.1 Primer design and chimera generation using the overlap extension PCR 
strategy  
Env was amplified as three separate fragments; F1, F2 and F3 (which were 
complementary at the 3’-ends), in a 5-step PCR method.  The F2 region was the region 
of interest.  The amplification required six primers, including the forward primer EnvA 
(5’-GGCTTAGGCATCTCCTATGGCAGGAAGAA-3’) and reverse primer EnvM (5’-
TAGCCCTTCCAGTCCCCCCTTTTCTTTTA-3’) 142 which bind at the start and at the 
end of env, respectively.  The remainder of the primers were designed as follows: 
29 
 
EnvA was used as a forward primer for the amplification of F1.  The reverse primer for 
F1 was designed to bind just upstream of the region of interest (F2) and had a ten base 
pair overlap with the forward primer for the amplification of F2.  The reverse primer for 
F2 was designed to bind to the 3’ terminal section of the region of interest, with a 5’ 
overlap with the F3 forward primer.  The F3 forward primer was designed to bind at the 
end of F2.  EnvM was used at the F3 reverse primer, and bound to the 3’ end of 
envelope gene (Figure 2.1).  To join the F1 and F2 fragments, the F1 and F2 PCR 
products were pooled.  Due to the introduced sequence overlap between the terminal 
regions of the two fragments, the forward strands from each fragment will prime an 
extension, merging it with the corresponding strand from the other fragment.  These 
were then amplified in the same reaction, using the EnvA and F2 reverse primers to 
make an F1F2 amplicon.  Similarly, the EnvA and EnvM were used to link the F1F2 
fragment to F3, thus generating a full length chimeric env sequence. 
The primers were named according to the targeted region of envelope (V1V2 or C3V4); 
which fragment they amplify (F1, F2 or F3) and lastly, the primer orientation (forward 
or reverse) (Appendix A).  The GC content and Tm of all primers were calculated using 
an online tool called IDT OligoAnalyzer (http://eu.idtdna.com/calc/analyzer), to ensure 
that primer binding would occur at a consistent temperature, for all of the various primer 
combinations. 
PCR amplification was carried out in 50 ul reactions containing 1X Phusion Buffer, 0.2 
mM dNTP, 0.25 mM of primers and 1 unit of Phusion enzyme.  The cycling conditions 
were set at 94 ⁰C for 3 min, 45 cycles of 94 ⁰C for 30 s; various melting temperatures 





Figure 2.1. Overlap extension PCR strategy.  A Fragment 2 is amplified 
from a neutralization sensitive envelope backbone using F2 forward (F2.for) 
and reverse (rev) primers.  The 5’-end of the F2 for primer is complementary 
to the 5’-end of the F1.rev primer.  While the 5’-end of the F2.rev primer is 
complementary to the 5’-end of the F3.for primer.  B. Fragments 1 and 3 
are amplified from the resistant envelope backbone.  Fragment 1 is 
amplified using EnvA is the forward primer and F1.rev as the reverse.  
Fragment 3, on the other hand, is amplified using F3.for as the forward and 
EnvM as the reverse.  C. Fragments 1 and 2 are linked together by the 
complementary regions introduced by the primers.  Primers EnvA and 
F2.rev are used to join the two fragments together to form one fragment.  D 
A complete envelope chimera is formed by joining the fragment from C with 
fragment 3 using the EnvA and EnvM primers. 
 
The construction of expression plasmids containing the chimeric envelopes was 
carried out as per section 2.11, followed by transformation into competent Top 10 E-




2.5.2 Primer design and chimera generation using the mega primer strategy 
The mega-primer approach uses two primers in a two-step PCR method 141.  These 
primers were the forward and reverse primers used to amplify (F2) in the overlapping 
PCR approach.  The 5’-ends of the primers were complementary to the sequences of 
envelope plasmid at the beginning and end of the region for which the chimera is being 
generated. 
In the first PCR step, F2 was amplified as in the overlap extension PCR strategy.  This 
amplicon was then gel extracted and purified, as described in section 2.7.  Generation 
of a chimeric HIV-1 envelope plasmid (step two) was done using similar PCR 
conditions as above, with the following exceptions: 100 ng of F2 was used as a ‘mega 
primer’ and 50ng of the neutralization resistant env expression plasmid as a template.  
The extension time was increased to 10 min, as the entire plasmid is amplified during 
this protocol. 
The amplification occurs when each strand of F2 acts as a mega primer on the 
respective strands of the template plasmid.  After the first cycle, hybrid plasmids are 
produced, containing one parental template strand and one newly synthesized strand 
containing the introduced chimeric sequence (namely, the mega primer).  From the 
second cycle onwards, both hybrid plasmids and fully chimeric plasmids are produced.  
The sample was then treated with 1 Unit of DpnI for 15 min to remove the original 
methylated env template (Figure 2.2).  The chimeric envelope plasmid was then 
transformed into competent Top 10 E.coli cells as described in 2.12 and purified as in 
section 2.18.  Successful generation of chimeric sequences was confirmed by Sanger 







Figure 2.2. Mega primer chimera generation strategy.  A. The region of 
interest (Fragment 2) is amplified using the designed primers.  These 
primers are complementary to the corresponding regions on the plasmid.  B 
The amplicon from ‘A’ acts as a mega primer in the second reaction and 
plasmid as the template.  The template is denatured, the mega primer 
anneals to the plasmid by complementarity, and extension is initiated from 
the primer 3’-end.  Extension proceeds following the rolling circle 
mechanism until the 5’- end is reached.  The mega primer replaces the 
corresponding region in the plasmid, forming the chimeric plasmid.  C. The 
parental plasmid is degraded by DpnI digestion.  The chimeric envelope 




2.6 Gel electrophoresis of PCR products 
PCR products were electrophoresed on agarose gels (0.8, 1 or 2% (w/v) agarose in 
1X TAE buffer (40 mM Tris base, acetic acid and 1 mM EDTA pH 8).  PCR products 
were prepared with 1X loading dye (0.25 (w/v) bromophenol blue, 30% (v/v) glycerol, 
0.25% (w/v) xylene cyanol FF,10X Gel Red) and electrophoresed at 100 V for 20 min 
in 1X TAE buffer.  Amplified DNA was visualized under UV light using a UVITEC 
UVIPro Silver Gel doc machine. 
 
2.7 DNA purification from agarose gel 
DNA was purified from agarose gels using the crystal violet method (Invitrogen, Life 
Technologies).  To prepare the gel, 40 ul of crystal violet was added to 50 ml 0.8% 
agarose gel, prepared as above.  Electrophoresis was carried out at 100 V for 30 min 
and the gel was visualized under white light.  Appropriately sized DNA fragments (~3 
kb) were excised from the crystal violet gel and purified using the Zymoclean™ Gel 
DNA Recovery Kit (Zymoresearch, Irvine, CA), following the manufacturer’s 
instructions.  The purified fragments were eluted in 10 µl DNA Elution Buffer and DNA 




2.8 Sequencing of HIV-1 envelope clones and chimeras 
Sanger sequencing of amplified DNA was performed at the Central Analytic Facility at 
the University of Stellenbosch, South Africa, on an ABI300 DNA Analyzer; using 
BigDye Terminator chemistry (Applied BioSystems, Foster City, CA).  HIV-1 gp160 
envelopes were sequenced using 12 overlapping primers (Appendix A).  
 
2.9 Sequence assembly and analysis.  
Sequences were edited and assembled in Sequencher® version 5.1 (Gene Codes, 
Ann Arbor, MI) to make full length envelope gp160 sequences.  Firstly, the 
chromatograms were inspected for ambiguous base calls (double peaks).  To qualify 
as an SGA sequence, all sequences that contain more than two double peaks were 
excluded from the analysis, as this indicates amplification from multiple templates.  The 
resulting SGA sequences were aligned using Clustal W, and a consensus sequence 
generated in Bioedit version 7 143.  Two online tools, one for generating a highlighter 
plot, showing sequence changes over time, 
(http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter.html), and another 
for plotting the entropy over time, at each position in the sequence, 
http://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy_two.html, were used to 
visualize sequence diversity.  Poisson Fitter 
(http://www.hiv.lanl.gov/content/sequence/POISSON_FITTER/poisson_fitter.html) 
was used to determine whether the distribution of the distance scores for the 
sequences could be fitted to the Poisson distribution.  The number of potential N-linked 
glycosylation (PNLG) sites was determined using the program N-glycosite 
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(http://www.hiv.lanl.gov/content/hiv-db/GLYCOSITE/glycosite.html).  The length of the 
variable loops was determined using the Variable loop characterization tool on Lanl 
(http://www.hiv.lanl.gov/cgi-bin/VAR_REG_CHAR/var_reg_char). 
 
2.10 Amplification of HIV-1 envelopes for cloning into a mammalian expression 
system 
Nested PCR reactions were carried out on first round PCR products from the SGA 
reactions (described in section 2.4) using the high fidelity polymerase Phusion Hot-
Start (New England Biolabs, Ipswich, MA, USA).  Each reaction contained 1 µl of the 
first round PCR DNA product, 1 Unit Phusion Hot Start Enzyme (Biolabs), 0.2 mM of 
each dNTP, 0.2 µM EnvM reverse primer (5’–
TTGCCAATCAGGGAAGTAGCCTTGTGT-3’), 0.2 µM Env1Arx forward primer, 
containing a 5’ CACC overhang allowing directional cloning, (Env1Arx: 5’ - CAC CGG 
CTT AGG CAT CTC CTA TAG CAG GAA GAA-3’;) and made up to 50 µl with distilled 
H2O.  The cycling conditions were set at: 94 ºC for 5 min, 45 cycles of 94 ºC for 30 s, 
55 ºC for 30 s, and 72 ºC for 5 min and a final extension step of 72 ºC for 10 min.  
Phusion reaction products were purified as per section 2.7.  
 
2.11 Generation of an mammalian expression vector containing HIV-1 envelope 
Pseudotyped Env expression vectors were prepared using the pcDNA™3.1/V5-His 
TOPO® TA Expression Kit (Invitrogen) according to the manufacturer’s instruction.  
The ligation of the purified envelope with the pcDNA3.1/V5-His-TOPO plasmid 
(Invitrogen) occurs through the annealing of the 3’-A overhangs on the envelope, 
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introduced by the Phusion polymerase, to the 5’-T overhangs on the linearized 
plasmid.  Ligation was performed in 6 µl reactions containing: 30 ng of envelope DNA, 
10 ng of the pcDNA3.1/V5-His-TOPO plasmid and 1 µl salt solution, made up to 6 µl 
with sterile water.  Reactions were incubated at room temperature for 5 min. 
 
2.12 Transformation of Top10 competent Escherichia coli (E. coli)  
Top10 competent Escherichia coli (E. coli) cells (Invitrogen) were used for the 
transformation of env-containing pcDNA3.1/V5-His-TOPO plasmid, using the heat 
shock transformation method specified in the pcDNA™3.1/V5-His TOPO® TA 
Expression Kit.  The ligated vector was incubated with the TOP 10 cells on ice for 30 
min, followed by heat shocking at 42 ⁰C for 30 s.  The transformed cells were incubated 
in Luria-Bertani Broth (LB) (1 % (w/v) Tryptone, 1% (w/v) yeast extract and 0.5% (w/v) 
Sodium Chloride) for 1 hour at 32 ⁰C, to express the ampillic resistance gene, following 
which they were plated out on luria agar (0.5% (w/v) peptone, 0.25% (w/v) yeast extract 
,0.1% (w/v) glucose and 1.5% (w/v) agar) containing 100 mg/ml carbenicillin antibiotic 
and incubated overnight at 32 °C. 
 
2.13 Screening of colonies for successful transformation 
Colony PCR (cPCR) was used to screen the transformants for successful cloning of 
env into the pcDNA3.1/V5-His-TOPO plasmid.  The cPCR reaction mix contained: 
0.25X Superrtherm Taq Buffer, 1 mM MgCl2, 0.25 mM dNTPs, 2 µM T7 forward primer 
(5´TAATACGACTCACTATAGGG-3’), 2 µM BGH reverse primer 
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(5´TAGAAGGCACAGTCGAGG-3’) and 0.0375 Units Supertherm Taq Polymerase.  
The cycling conditions were set at: 94 ºC for 30 s, 35 cycles of 94 ºC for 30 s, 51 ºC 
for 30 s, and 72 ºC for 3 min and a final extension step of 72 ºC for 10 min.  Products 
was separated on 1% (w/v) agarose gel and viewed under UV light.  The presence of 
a 100 bp fragment was used to identify positive colonies. 
 
2.14 Large scale plasmid preparation 
Colonies, identified as positive by colony PCR, were inoculated into 5 ml of LB with 
100 mg/ml of carbenicillin and incubated for 6 hours at 32 ºC.  This starter culture was 
then transferred to a 1L flask containing 100 ml LB and 100 mg/ml carbenicillin and 
incubated overnight at 32 ºC.  The env-containing pcDNA 3.1/V5-His TOPO plasmid 
was prepared from 50 ml of overnight culture using the QiAprep spin Miniprep kit 
(Qiagen) following the manufacturer’s instructions. The plasmid DNA was eluted in 50 
µl sterile water and the concentration determined using a NanoDrop. DNA was stored 
at -20 ⁰C, until use.  
 
2.15 Cell line maintenance and preparation 
Cell lines of adherent TZM-bl and HEK293T cells were maintained in T75 flasks 
containing complete growth medium (GM) (Dulbecco’s Modified Eagle Meduim 
(DMEM) with L-glutamine, sodium pyruvate, glucose and pyridoxine (Gibco BRL Life 
Technologies), 10% Fetal Bovine Serum (FBS) heat inactivated at 56 ⁰C for 1 hour, 10 
mM HEPES (N-2-Hydroxyethylpiperazine-N’-2-Ethanesulfonic Acid) (Gibco BRL Life 
Technologies), 50 µg/ml Gentamicin solution (Sigma-Aldrich).  Cells were incubated at 
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37 ⁰C, with 5% CO2 and 90% humidity until confluent, usually 2-3 days.  The 
monolayers were disrupted at confluency by treatment with Trypsin-EDTA (0.25% 
trypsin, 1 mM EDTA) (Invitrogen) as follows: Growth medium was removed from the 
flask.  The monolayers were washed with 5 ml Phosphate Buffer Saline (PBS, without 
magnesium or calcium), to remove residual serum.  TZM-bl and HEK293T cells were 
then incubated with 2.5 ml and 1 ml 0.25% Trypsin-EDTA respectively, to disrupt 
adherence, following which, cells were incubated at room temperature for 5 min for 
TZM-bl and 1 min for HEK293T cells.  Trypsin activity was disrupted by addition of 10 
ml GM. 
 
2.16 Cell counting  
10 ul of trypsinized cells on GM were stained with 10 ul 0.4% Trypan Blue (Sigma-
Aldrich) and counted using a hemocytometer, with cells counted in the four major 
quadrants. The total number of cells contained in 1 ml of the typsinized cell suspension 
was obtained by multiplying the number of cells counted by 5000 (dilution factor * 
10 000 cells/ml).  
 
2.17 Generation of pseudotyped viruses by transfection of HEK293T cells using 
molecular clones 
Env-pseudoviruses were generated by co-transfection of an env-deficient plasmid, 
pSG3Δenv, and a vector containing a cloned envelope, i.e. env-pcDNA3.1/V5-His-
TOPO plasmid, into HEK293 T cells.  Three million HEK293T cells were grown 
overnight in T75 flasks under the following conditions: 5% CO2, 90% humidity and 37 
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°C.  The cells were transfected with 4 µg of envelope-pcDNA3.1/V5-His-TOPO and 8 
µg of pSG3Δenv, using the polyfect transfection kit, according to the manufacturers 
instructions (PolyFect® Transfection Reagent Handbook, September, 2000).  Briefly, 
non-phenol red DMEM (Gibco, Life Technologies, Carlsbad, CA) was added to the 
DNA, following which 40 µl Polyfect Transfection Reagent (Qiagen) was added and 
the transfection mixture incubated at room temperature for 10 min.  Polyfect allows 
formation of DNA complexes that facilitate efficient transfection.  Complete GM was 
slowly added to the mix, which was transferred to the T75 flask of the HEK293T cell 
monolayer.  Cells were incubated for 48 hours at 37 ºC and 5% CO2 to express 
pseudovirus.  Functional Env is produced from the pCDNA plasmid while additional 
components required for virion assemply are produced from the pSG3Δenv plasmid.  
This produces virus capable of only one infection cycle, which are thus termed 
pseudovirus.  Pseudovirus-containing media was harvested after 48 hours and passed 
through a 0.45 µm filter to remove any cells.  The serum concentration of the media 
was adjusted to 20% by addition of 100µl heat inactivated FBS and stored at -80 °C.  
 
2.18 Titration of pseudovirus particles for neutralization assay (TCID50 assay) 
Pseudoviruses are called as such because of their inability to produce infectious virions 
due to the separation of the envelope from the other genomic regions.  Thus, they can 
only undergo one cycle of replication, infectivity is detectable using an engineered cell 
line.  TZM-bl cells are  engineered to express high levels of CD4 and CCR5-receptors 
required for HIV-1 infection.  Once the cells are infected, the viral transcription factor 
Tat initiates HIV-1 replication,  This results in the expression of HIV-1 genes, as well 
as a luciferase reporter gene which has been engineered into the TZM-bl cell line.  To 
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quantify the infectivity dose, a luciferase substrate is added.  This is cleaved by the 
luciferase enzyme, giving off luminiscence which is detected on a luminometer as 
Relative Light Units (RLU).  
To determine the infectivity dose of the pseudoviruses generated above, the 
pseudovirus was diluted in GM in a 96 well plate, using a fourfold serial dilution, carried 
out in duplicate.  TZM-bl cells (10,000 cells/100 µl) containing 25 µg DEAE-Dextran/ml 
were added per well.  The pseudovirus was incubated with these cells for 48 hours at 
37 ⁰C, 5% CO2 and 90% humidity.  The infectivity of the pseudovirus was inferred from 
the RLU which are produced as a result of the virus infecting the cells.  The BrightGlo 
Luciferase assay was used to determine the RLU produced at each of the dilutions.  
To perform the assay, 100 µl of growth media was removed from the well of the plates 
containing the virus and cell mixture before adding 100 µl BrightGLo luciferase 
substrate.  The luciferase enzyme in the BrightGlo mix reacts with the substrate to give 
off luminescence, which was detected on a Promega Glomax 96 microplate 
luminometer. The TCID50 was taken as the pseudovirus dilution that gives at least 
10 000 RLU.   
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2.19  Neutralization assay using pseudotyped viruses 
The TZM-bl cell line expresses both the CD4 and CCR5 co-receptors required for HIV-
1 infection.  During infection, luciferase is expressed under the direction of a Tat-
induced promoter (Tat is an HIV transcription factor).  The amount of luciferase 
produced, directly correlates with the number of successful infections.  The 
neutralization assay was performed using a single-round TZM-bl reporter assay in 
duplicate, in a 96-well plate format.  Pseudovirus was incubated with eight threefold 
dilutions of antibody, containing heat inactivated plasma (incubated at 56 °C for one 
hour to remove complement activity which may interfere with the neutralizition assay) 
and incubated for at least 45 min at 37 °C, CO2, 90% humidity.  TZM-bl cells (10 000 
cells per well in 100 µl growth medium) were added to the pseudovirus-plasma mixture 
and incubated for 48 hours at 37 °C, CO2 and 90% humidity.  After 48 hours, the TZM-
bl cells was lysed and evaluated for luciferase activity.  The percentage infectivity was 
calculated using the macro luminescence sheet (available from www.hiv.lanl.gov).  
This sheet calculates the percentage neutralization for each of the plasma dilutions.  






The design of immunogens that can elicit broadly neutralizing responses remains a 
priority in HIV-1 vaccine research.  There is evidence that HIV-1 diversification may 
contribute to the development of broadly cross neutralizing antibodies.  Recent studies 
in two individuals showed that viral escape from antibody pressure may have facilitated 
the maturation of the antibody response to develop breadth through the presentation 
of Env variants 133 134.  Whether or not this pattern of concomitant viral evolution and 
antibody maturation leading to development of bnAbs can be generalized to other HIV-
1 infected individuals is unknown. The aim of this thesis was characterise early ssnAb 
responses and the associated viral evolution in one individual from the CAPRISA004 
cohort, and to determine the relationship between epitopes targeted by strain specific 
neutralizing and the broadly neutralizing antibodies.   
 
3.1  Study participant 
This study performed a detailed analysis of viral evolution in an HIV-1 in an infected 
woman, CAP292, who was in the placebo arm of the CAPRISA004 study that tested 
the effectiveness of a tenofovir microbicide gel in preventing HIV-1 infection in women 
13.  CAP292 was infected in March 2008 and enrolled into the CAPRISA002 acute 
infection study in April of the same year.  She developed some cross-neutralizing 
responses at 12 months post infection, and by three years post infection plasma from 
this participant neutralized 56% of viruses in a heterologous multi-clade panel of HIV-
1 pseudoviruses (P. Moore, personal communication).   
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At enrolment into the cohort, CAP292 had a high viral load of 458 000 copies/ml, 
consistent with acute infection (Figure 3.1).  The initial control of viral load to 34 700 
copies/ml at 14 w.p.i was followed by a marked increase to 233 000 copies/ml by 30 
w.p.i.  The CD4+ T cell count was 510 cells/µl at enrolment and declined to 232 cells/µl 
by 21 w.p.i with the concomitant increase in viral load during this time period.  Therapy 
was offered to all participants whose CD4 T cell count fell below 350 cells/µl, according 
the prevailing national guidelines.  At this time CAP292 refused therapy (N. Garrett 
personal communication).  By 186 w.p.i, the viral load declined to 32 000 copies/ml 
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Figure 3.1. Viral load and CD4+ T cell trajectory in CAP292.  
The black line at 350 cells/µl, represents the CD4 count threshold  







3.2 The CAP292 transmitted/founder (t/f) virus envelope 
To determine the kinetics of early ssnAb responses it was necessary to identify the 
env sequence of the virus that established the infection, the transmitted/founder (t/f).  
Due to rapid escape from nAbs, ideally this requires sampling prior to immune 
pressure, or at least prior to the development of nAb responses.   
To identify the t/f env sequence in CAP292, SGA followed by sequencing was carried 
out 61.  To generate single genome amplicons, cDNA was diluted such that after 
amplification, there were less than 30% positive reactions, which according to the 
Poisson distribution, implies a high likelihood that amplification was from one template 
in more than 80% of positive reactions 61.  Whilst it was optimal to determine the t/f env 
at the closest time point to infection, amplification from the five w.p.i sample was 
unsuccessful despite repeated attempts at RNA extraction and re-amplification.  It was 
suspected that the RNA from this sample had degraded, thus, RNA from the next 
available time point (6 w.p.i.) was used.  The amplification of env from cDNA at a 1:81 






Figure 3.2. A representative for envelope single genome amplification 
(SGA) of CAP292 at 6 weeks post infection. The SGA amplicons were 
electrophoresed on a 1% agarose gel with a 1kb molecular weight marker (M) 
(Thermo Fischer Scientific, Waltham, MA, USA).  Positive amplification is 
indicated by the presence of distinct DNA fragments at 3kb (indicated by 
arrows).   
 
 
A total of 16 SGA sequences, which had no nucleotide ambiguities, were used in 
further analysis.  We determine the multiplicity of infection based on criteria established 
by Keele and colleagues (2008) whereby an infection was identified as being founded 
by a single variant if it met the following criteria: no shared mutations in the population; 
low genetic diversity; Poisson distribution of hamming distances; and sequences 
conforming to a star-like phylogeny.   
The sequences in CAP292 had very low diversity, with a mean genetic distance of 




pairwise measure of the number of base differences between sequences, shows a 
Poisson distribution consistent with single variant infection (Figure 3.3).   
 
 
Figure 3.3. Hamming distance frequency distribution. The frequency was plotted 
as the number of sequences with the same hamming distance.  The line of best fit is 
indicated in red.  The hamming distances was plotted from an alignment of 16 SGA 
sequences from the 6 w.p.i time point.  The length of the sequences was 2586 
nucleotides.   
 
The sequence phylogeny was assessed using a neighbour joining tree and the 
diversity analysed in the highlighter plot (Figure 3.4).  The highlighter plot 
(www.hiv.lanl.gov/highlighter), ‘highlights’ the nucleotides which differ from the 
consensus sequence, in each sequence in a nucleotide alignment.  The neighbour 
joining tree showed limited divergence, with two sequences: 1A_6w.p.i and 9H_6w.p.i 
being identical to the generated consensus sequence.  The sequences 6D_6w.p.i, 
8C_w.p.i, 1D_6w.p.i and 1E_6w.p.i formed one sub-lineage, whilst a second sub-
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lineage consisted of the 10C and 3B_w.p.i sequences.  The sequences that formed 
the first sub-lineage (6D, 8C, 1E 1D_6w.p.i) had a shared mutation at position 2191, 
and the sequences 1D_6w.p.i and 1E_6w.p.i had an additional shared mutation at 
position 1103.  Similarly, in the other sub-lineage consisting of the sequences 10C and 
3B_w.p.i, there was a shared mutation at position 1629.  As this individual had been 
infected for approximately 6 weeks, we propose that the observed shared mutations 
between sequences was a result of mutations introduced and replicated in early 









Figure 3.4. Analysis of CAP292 SGA sequences at 6 weeks post infection.  The 
sequences are compared to the consensus (master sequence) in the nucleotide 
highlighter plot (left).  Variations from the consensus are represented by the coloured 
stokes (key is shown on the left).  The neighbour joining tree (middle), rooted at the 
consensus, and shows the phylogeny of the sequences. The distance scale bar is 




































The distribution of the DNA distances fit the Poisson model (Figure 3.3), and this 
together with star-like phylogeny (Figure 3.4) and low diversity suggested infection by 
a single viral variant.  There were two SGA sequences that matched the consensus 
exactly.  One of these, sequence 1A_6w.p.i, was chosen as the representative of 
CAP292 t/f env.   
 
3.3 Neutralization profile of the transmitted/founder (t/f) virus. 
Strain-specific neutralizing antibodies (ssnAb) are the first neutralizing antibodies to 
develop against HIV-1 144 .  In order to determine the timing of development of ssnAb, 
the SGA sequence 1A_6w.p.i (identical to the consensus sequence) was cloned to 
generate the CAP292 t/f env pseudovirus.  The clone was sequenced to confirm that 
no errors had been incorporated during the PCR and cloning steps.  The CAP292 t/f 
env pseudovirus was subsequently tested against plasma spanning the first year of 
infection for neutralization sensitivity. 
The first neutralizing antibody response was detected at 14 w.p.i, at low potency (ID50 
of 1:92) (Figure 3.5).  The antibody titers appear to track the increase in viral load 
rising to ID50 of 1:782 by 30 w.p.i and 1:1139 by 58 w.p.i, where viral load and 
neutralization titers stabilized.  The concomitant increase in viral load with 
neutralization titer suggested that the strain-specific response had no impact on viral 









































Figure 3.5. Neutralization kinetics of the transmitted/founder virus (blue line) 
and viral load (red line).  The increase in viral load after peak viremia coincided 
with emergence of the first neutralizing antibodies at 14 w.p.i.  The nAb titers 
increase steadily up to 58 w.p.i.  The black line indicates the limit of detection for 
neutralization sensitivity (ID50 < 1:50). 
 
3.4 Evolution in Envelope over three years  
Neutralizing antibody responses drive viral escape, which is typically mediated by 
insertions and deletions, and shifts in potential N-linked glycan sites.  A lowered net 
negative charge of Env has also been associated with resistance to neutralization 112, 
and there is evidence that the net charge of virus and antibody co-evolve over time  
134.  To identify sites under antibody pressure, we examined the env viral sequences 
from longitudinal time points. 
A total of 59 SGA sequences were generated from five time points: 6 w.p.i (prior to 
nAbs); 14 w.p.i (around the time of strain-specific nAbs developed; 30 w.p.i.; 58 w.p.i 
(at the time development of early neutralization breadth); and 186 w.p.i (peak 
neutralization breadth).  An average of 11 SGA derived sequences were generated 
per time point, with the phylogenies illustrated in Figure 3.6.  The sequences clustered 
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according to time post infection, except at 6 and 14 w.p.i, which made up a single 
cluster due to a low level of sequence diversity.  The intermixing of the sequences from 
these two early time points suggested that there was limited selection between time of 
infection and at first detection of neutralizing antibodies at 14 weeks.  The dramatic 
shift of the viral populations after 30 w.p.i. suggested strong selective pressure.  The 
6A_30w.p.i sequence did not cluster with the rest of the sequences at this time point.  
Instead this sequence appears to be the ancestor of the two clusters at 30 w.p.i and 
58 w.p.i.  Similarly at 58 w.p.i the sequences 4B_58w.p.i and 11C_58 w.p.i formed a 
cluster separate from the rest of the sequence at 58 w.p.i (Figure 3.6).  The cluster at 
158 w.p.i consisted of two distinct sub-lineages suggesting two separate escape 































































Figure 3.6. Phylogeny of longitudinal env 
sequences.  The neighbour joining tree show the 
phylogeny of the env sequences derived from five 
longitudinal time points:  6    , 14   , 30   , 58    and 186 
w.p.i   .  Four lineages were formed, each 
corresponding to the sampling time point, with the 
exception of the first lineage which consisted of 
sequences from the 6 and 14 w.p.i time points.  Two 
sub-lineages make up the lineage at 186 w.p.i.  Arrows 




Divergence, defined as the average hamming distance (aHD) from the t/f env 
consensus sequence, increased gradually over time (Figure 3.7).  The aHD at 6 w.p.i 
was 1.78, and increased to 52.14, 67.52 and 131.81 by 30, 58 and 186 w.p.i 
respectively.  To estimate env variation within viral populations we calculated the 
standard deviation (SD) from the aHD at each time point.  There was very little 
sequence diversity at 6 w.p.i (SD 1.7), indicating little selective pressure in early 
infection.  After the development of nAbs at 30 w.p.i the diversity increased to SD 17, 
and interestingly was maintained at SD 18 at 58 w.p.i and at 186 w.p.i.  Although the 
high diversity at the latter time points was expected due to the increase in antibody 
selective pressure, it was of interest that there was similar diversity at each time point 
from 30 weeks suggesting some selective pressure on viral populations constraining 
population diversity. 
 
Figure 3.7. Divergence and diversity of sequences at sequential time points. 
Divergence was calculated as the average hamming distance (aHD) from the t/f 
sequences.  The sequence diversity, calculated as the standard deviation (SD) of 




3.5 Evolution in putative antibody sites 
For identification of putative nAb escape mutations, the sequences were aligned to the 
t/f sequence and the variation from the t/f sequence was visualized on a highlighter 
plot (Figure 3.8).  Putative immune escape was identified as shared mutations that 
became fixed over time.  As escape is typically facilitated by changes in variable loop 
length, N-linked glycan sites and Env net charge, and elongation of the variable loops 
has been shown to confer resistance to neutralization 112, we also analysed changes 
in these properties over time.   
The highlighter analysis shows very little sequence variation between the 6 and 14 
w.p.i time points (Figure 3.8).  The mutations that occurred during this time period 
were mostly scattered across envelope, suggesting random viral evolution which is 
consistent with a lack of strong antibody pressure.  There was, however, a G459S 
shared mutation in the V5 region (Figure 3.9).  This mutation was found in one 
sequence at 6 w.p.i, one at 14 w.p.i and in all but one of the sequences at 30 w.p.i but 
not at subsequent time points.  Another shared mutation (E735K) was found at position 
in the intracellular domain of gp41 in 6/24 of the sequences at 6 and 14 w.p.i combined 
(Figure 3.9).  Similar to the mutation in V5, the E735K mutation (all references are to 
HXB2 numbering) was not detected at any of the other time points.  This data indicates 
selective pressure that acted on viral variants circulating before detection of the first 
neutralizing response, although these mutations may also have been introduced by 
chance.   
The first persistent mutations were detected at 30 w.p.i, and occurred mostly in the 
gp120 region (Figure 3.8).  Deletions were detected in the V1V2 region, while non-
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synonymous changes were identified in multiple regions of envelope.   The gp41 was 
particularly conserved, having only a few persistent nonsynonymous mutations at 30 
w.p.i, however there were more nonsynonymous mutation in the gp41 at 186 w.p.i, 
after development of the broadly neutralizing response.  
 
Figure 3.8. Synonymous/non-synonymous plot analysis of 
envelope SGA sequences over time.  SGA sequences were 
generated from five sequential time points.  All sequences are 
compared to the master sequence 1A_6 w.p.i t/f.  Nonsynonymous, 
synonymous mutations and gaps are represented by green, red and 
gray respectively.  The different regions of env are annotated below 








Figure 3.9. Evidence of early immune pressure in the V5 and intracellular 
domain of gp41.  Amino acid alignment of the V5 region A, shows the G459S 
mutation in the sequences 9D_6w.p.i, 1D_14 w.p.i and in all but two sequences at 
30 w.p.i.  In gp41 B, an E735K mutation occurred in the intracellular domain in 6/24 
sequences at 6- and 14w.p.i combined. HXB2 numbering was used. “n” indicates the 
number of sequences matching the clone next to which n appears.  
 
 
Analysis of loop-length and shift or change in N-glycan site identified a marked 
shortening of the V1V2 loop from a median of 77 amino acids following transmission 
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to 62 amino acids at 186 w.p.i (Figure 3.10A).  This was accompanied by a reduction 
in the number of potential N-linked glycan sites from eight to 6 between 6 and 186 
w.p.i.  The length of the V3, V4 and V5 regions was constant throughout infection.  
However, variation within these loops included an increase in the number of 
glycosylation sites, which tended to increase by one site by 186 w.p.i in the V3 and V4.  
The overall net charge was neutral by 186 w.p.i, from a charge of -2 in the t/f virus 
(Figure 3.10B).  While the net charge was constant in the V3 region, in V4, the charge 
increased from +1 to +2 at 186 w.p.i.  Inversely, the charge changed from -2 at 
















































































































































Average Net charge 
w.p.i V1V2 V3 V4 V5 
6 -2 4 -1 -2 
14 -2 4 -1 -2 
30 -1 4 -1 -2 
58 -2 4 0 -2 
186 0 4 1 -3 
A B 
C 
Figure 3.10. Variable loop region 
characterisation over time.  A. Average 
variable loop length variation, B. average 
number of potential N-linked glycosylation sites 
and C. average net charge (red: negative, blue: 
positive, white: neutral charge). The error bars 
indicate the standard deviation in the variable 
loop length and number of potential N-linked 




Together, these data showed that Env evolved through changes in the variable loop 
lengths, number of glycosylation sites and net charge.  Most of these variation 
occurred in the V1V2 region suggesting that this regions largely contributed to the 
changes in the Env of successive viral populations.  
Molecular characterisation of the V1V2 region (Figure 3.11) showed a deletion 
between positions 132 and 145, which was first introduced at 30 w.p.i and 
maintained until 58 w.p.i.  This deletion resulted in the disruption of an N-linked 
glycosylation site at position 135.1 in the t/f virus, where 135 would be the HXB2 
position and the decimal point representing insertions relative to the HXB2 number.  
At 186 w.p.i, the viral populations were split into two subpopulations: the first 6 
sequences in the alignment at this time point (here forth referred to as sub-lineage 1) 
showed several distinct sequence changes from the other five sequences (sub-
lineage 2), indicating that these two lineages may be the result of alternative escape 
pathways.  In the sub-lineage 1 sequences, a deletion between 135 and 144 resulted 
in abrogation of two N-linked glycan sites at positions 135.9 and 141.  Sub-lineage 2 
had the T135.6N and G135.8T mutations that introduced an N-linked glycan site at 
position 136.6.  An E169K charge change mutation was detected in sub-lineage 1, 
while sub-lineage 2 had an R170K mutation, maintaining the positive charge at this 
position.  A substitution of N to T at position 135.1 shifted the N-linked glycan site 
from 135 to 133 in both the sub-lineages.  The N-linked glycan site at position 186 
was removed by the S189N at 30 w.p.i and deletion of N187 at subsequent time 




These data show that the V1V2 evolved through deletions associated with the 
removal of N-linked glycan sites, in sub-lineage 1, while, in contrast, insertions in 
this variable region in sub-lineage 2 introduced N-inked glycan sites.   
 
Figure 3.11. Amino acid highlighter analysis of the V1V2 of HIV-1 envelope 
over time.  The blue and orange boxes separate the two sub-lineages circulating at 
186 w.p.i.  Sub-lineage1 is shown in the blue box, and sub-lineage 2 in the orange.  
Amino acid identity is shown as dots (.), deletions as dashes (-).  The blue bars 
represent potential N-linked glycan sites.  HXB2 numbering is shown below the 
alignment.   
 
 
The alpha-2 helix in the C3 region is a target of strain-specific neutralizing antibodies 
in subtype C HIV-1 infection and variations in this epitope have been shown to confer 
neutralization escape 145.  The C3 and V4 regions are in close proximity on Env and 
form a conformational epitope targeted by the strain-specific neutralizing antibodies 
146.  In the C3V4 region most of the persistent changes were due to point mutations 
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(Figure 3.12).  Of note, the S334N and N336T mutations shifted the PNLG site from 
332 to 334 at 186 w.p.i.  This region is a common target of bnAbs that target the V3 
glycan supersite 147.  The E337K introduced a positive charge.  More charge 
changes were introduced by the mutations E337K, E347K and K348E.  Sub-lineage 
2 at 186 w.p.i had an R348K mutation that did not modify the charge, but could 
potentially interfere with binding of nAbs by steric hindrance, owing to the bulkier 
structure of R when compared to K.  The N-linked glycan site at 359 shifted to 357 
through the mutations D357N and N359T/S in 4/10 sequences at 58 w.p.i.  This 
glycan was completely removed in sub-lineage 1 at 186 w.p.i, but maintained in sub-
lineage 2 at the initial position 359.  This provided further evidence that sub-lineage 
1 and 2 followed different escape pathways.  Between positions 404 and 415, sub-
lineage 1 had a six amino acid insertion that results in introduction of an N-linked 
glycan site.  Sub-lineage 2 had a three amino acid insertion that added an N-linked 
glycan site.   
In conclusion, these data show a gradual increase in divergence from the t/f 
sequence, and an increase in env diversity after detection of neutralizing antibodies.  
Most of the diversity was attributed to changes in the V1V2 region along with the 
C3V4 region, and were thus proposed to be putative antibody targets to strain 
specific nAbs.  The difference in the sub-populations at 186 w.p.i in both the V1V2 
and C3V4 regions suggested that the viral populations were diversifying under two 
sources of selective pressure, possibly neutralizing antibodies with different 
specificities; or viruses were exploring two separate pathways to escape a single 
specificity. The various potential escape mutations presented here show the 







Figure 3.12. Amino acid highlighter analysis of the C3V4 of HIV-1 envelope over 
time.  There were two sub-lineages at 186 w.p.i shown in the blue box (sub-lineage 1) 
and orange box (sub-lineage 2).  The blue vertical bars represent N-linked glycan sites.  
HXB2 numbering is shown below the alignment.  Amino acid identity is shown as dots 
(.), deletions as dashes (-). 
 
3.6 Neutralization sensitivity of later viruses 
To evaluate the different effects of viral evolution on neutralization sensitivity, one 
representative SGA amplicon was selected from each of the lineages at: 30, 58 and 
186 w.p.i, indicated on the phylogenetic tree (Figure 3.6).  The representative 
amplicons were chosen based on having the most number of mutations in the 
population, and therefore representing the most potential escape mutations.  
Neutralization sensitivity was not evaluated for the 14 w.p.i viruses due to the low 
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sequence variation and limited evidence of selection between this time point and the 
t/f sequences.  We thus expected that the antibody kinetics would not be significantly 
different from the t/f virus.   
Because strain-specific neutralizing antibodies target the virus that elicited them, we 
expected that the antibodies produced in response to the t/f virus would be ineffective 
against the 30 w.p.i viral variant.  Likewise, the antibodies targeting the 30 w.p.i variant 
would likely not neutralize the escaped virus at 58 w.p.i.  Furthermore, it is well 
documented that generally there is little to no contemporaneous neutralization in early 
infection due to rapid nature of viral escape 148 149.  We would thus expect that the 
neutralization curves to shift incrementally to the right to reflect contemporaneous 
escape.  The generated representatives of envelopes from the different time points 
were tested against plasma spanning the first year of infection (Figure 3.13).   
No contemporaneous neutralization was observed up until 30 weeks, at which point a 
very low level of contemporaneous neutralization was detected.  As expected, viruses 
were neutralized by serum collected after virus sampling (Figure 3.13A).  At the first 
time point where breadth was detected (58 w.p.i), there was evidence of modest 
sensitivity to contemporaneous neutralization (ID50 1:94).  The t/f virus was the most 
sensitive clone, all the viral variants that emerged later were less sensitive to 
neutralization (Figure 3.13B).  There was an increase in titer to CAP292_30w.p.i such 
that CAP292_30 w.p.i became more sensitive to neutralization than the t/f virus by 58 








These data show sequential escape from neutralizing antibodies, with low level 
contemporaneous neutralization of the CAP292_58 w.p.i virus illustrating incomplete 
escape at this time point.  A high titer responses had developed by 30 w.p.i, which may 
be due to maturation of the nAb lineage, or the development of additional nAb 
responses to the virus. 
 
3.7 Putative strain-specific neutralizing antibody targets 
Our sequence data analysis showed changes in the length and glycosylation of the 
V1V2 over time.  Additionally, the C3V4 region evolved by amino acid charge changes 
and shift in the N-linked glycan sites.  Although there were other mutations in the other 
regions of Env, the V1V2 and the C3V4 regions have been identified as common 
targets for strain-specific neutralizing antibodies 104.  We thus focused our attention of 
 






















Figure 3.13. Neutralization sensitivity of CAP292 viruses in the first 
year post infection.  This graph shows the kinetics of the responses at 
various time points within the first year of infection against the t/f, 30 
week, 58 week and 158 week clones 
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these regions, and generated chimeric viruses to investigate whether the V1V2 and 
C3V4 regions were strain-specific neutralizing antibody targets in CAP292.   
The chimeras were generated by introducing the V1V2 and C3V4 from CAP292 
transmitted/founder virus into the envelope of CAP239 which showed resistance to 
neutralization by CAP292 ssnAb.  This was done using two chimera generation 
strategies (see Figure 2.5 for the strategies).  Using the overlap extension PCR 
strategy, three fragments (referred to as F1, F2 and F3) of envelope were amplified to 
make the V1V2 (Figure 3.14A) and C3V4 (Figure 3.14B) chimeras.  F1 and F3 were 
amplified from an unrelated envelope of CAP239, whilst F2 – the region of interest – 
was amplified from the CAP292 t/f envelope.  F1 and F2 were linked (Figure 3.14C), 
and the resultant fragment (F1F2) was linked with F3 to complete the full length 




Figure 3.14. Agarose gel (1%) showing amplified fragments generated using 
the overlap extension PCR.  A. Amplified fragments for generation of the V1V2 
chimera.  B.  Amplified fragments for C3V4 chimera generation. C.  Linked fragments 
F1 and F2 to make F1F2.  D. F3 linked to F1F2 to complete the chimera (F1F2F3). 
 
An alternative chimera generation strategy – mega primer approach (Figure 3.15) – 
was performed concurrently with the overlapping fragment PCR to improve the 
chances of successful cloning.  In this method, F2 was amplified as above.  This 
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amplicon was then used as a mega primer to make chimeric env plasmid.  The region 
of the plasmid corresponding to F2 was replaced with the CAP292 F2 to make the 
chimeric 8kb envelope plasmid (Figure 3.15).  This method produced a chimeric env 
plasmid identical to the method above, but required fewer PCR reactions.  
 
Figure 3.15. 1% Agarose gel showing envelope plasmid amplified using the 
mega primer approach.  The fragments shown are the V1V2 (left) and C3V4 (right) 
chimeric envelope plasmids. 
 
The DNA bands observed (Figure 3.15) were approximately 10kb in size, instead of 
the expected 8kb.  This may have been due to the plasmid being in an open circle 
conformation, which is known to cause slower migration during gel electrophoresis.  
Chimeras generated through both strategies were confirmed by Sanger sequencing to 
have incorporated the correct sequences: F1 and F3 matched the CAP239 env, and 
F2 matched the CAP292 env.  The sequences of the chimeras generated through the 
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mega primer approach are shown in Figure 3.16 and these were used for subsequent 







Figure 3.16 Confirmation of chimerism.  The sequences of the chimeric viruses 
239.292.239_V1V2 in (A) and 239.292.239_C3V4 in (B) are aligned to the CAP 
292 and CAP 239 env backbones.  In both instances, the sequence of the 
chimeric virus matches that of the CAP 292 backbone in the specified regions.   
 
Chimeric pseudoviruses were generated from the chimeric env plasmids and tested 
against plasma spanning the first year of infection in neutralization assays.  The 
insertion of CAP292 V1V2 into the neutralization resistant CAP239 backbone to make 
the 239.292.239_V1V2 chimera, showed acquisition of sensitivity to neutralization after 
21 w.p.i, but was less sensitive than the CAP292 t/f virus (Figure 3.17).  Similarly, the 
C3V4 region inserted into the CAP239 backbone to make the 239.292.239_C3V4 
chimera introduced sensitivity into the CAP239 virus (Figure 3.17)  
The curve of 239.292.239_C3V4 chimera showed neutralization sensitivity at 14 w.p.i, 
similar to the curve of the t/f virus, suggesting that the initial antibody response targeted 
the C3V4 regions.  The fact that the response did not recapitulate that of the t/f virus, 
suggested that there might have been other antibody specificities during this time.  The 
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initial response was followed by a response to the V1V2 regions 7 weeks later.  At 21 
w.p.i, the sum of the titers (ID50 1:728 and ID50 1:939) amounted to titers comparable 
to those acquired for the t/f virus (ID50 1:1568), recapitulating the response to the t/f.  
This suggested that both anti-C3V4 and anti-V1V2 antibodies were responsible for 
neutralization.  The responses peaked at 30 and 38 weeks for C3V4 and V1V2 
respectively, with the V1V2 levelling at a lower titer compared to C3V4.  These results 
suggest that both these regions were targeted by the strain specific response during 
acute infection. 
























Figure 3.17. Mapping the strain-specific response in CAP292.  The generated 
chimeras were tested against plasma spanning the first year of infection.  The nAb 
titers are represented over time. 
 
As the backbone can influence the presentation of epitopes, chimeras were 
constructed to determine whether mutation within these regions mediated escape.  
CAP292_30 w.p.i escaped virus was used as the env backbone (Figure 3.18).  These 
chimeras were generated by replacing the V1V2 and C3V4 of the CAP 292_30 w.p.i 
virus with the same region from the neutralization sensitive CAP292 t/f virus.  In this 
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way, we were able to generate a virus with the t/f V1V2 (30w.p.i.t/f_V1V2.30w.p.i) and 
the 30 w.p.i virus with the t/f C3V4 (30w.p.i.t/f_C3V4.30w.p.i).  The representative 
pseudoviruses were tested against plasma from the first year of infection.  The 
30w.p.i.t/f_V1V2.30wpi chimera almost entirely overlapped with the t/f neutralization 
curve suggesting that escape from V1V2 response shown to emerge at 21 weeks post 
infection is nearly entirely mediated by V1V2 by 30 w.p.i.  In contrast, only partial 
escape from the C3V4 response is mediated by changes in C3V4 of the 30 week clone, 
suggesting additional escape mutation elsewhere.  This also suggested that the 
mutations acquired by CAP292_30w.p.i mediated escape.  The chimeric virus 
recapitulated the initial response to the infecting virus by 38 w.p.i and become more 
sensitive by 58 w.p.i, suggesting the V1V2 region was the sole target of antibodies at 
this time.  There was a slight acquisition of sensitivity in the 30w.p.i.t/f_C3V4.30w.p.i 
chimeric virus at 30 w.p.i, suggesting that C3V4 targeting antibodies had begun to 
emerge at this time.  Additionally, this suggested that the mutations acquired in the 
C3V4 region mediated partial viral escape.   
























Figure 3.18. Neutralization curves of chimeric viruses using 




These results, using the native CAP292_30w.p.i backbone, differed somewhat from 
those where the CAP292 backbone was used.  Namely, the C3V4 responses appear 
to be much greater for the CAP239 backbone chimeras, such that the C3V4 is 
implicated is the initial antibody target.  The table below shows the differences in the 
characteristics between the two backbones used, which may be responsible for the 
differential neutralization sensitivity.   
 
Table 1. Variable loop characteristics of the two  
Env backbones used for chimera generation 
 
Because the CAP292 backbone was close to the native virus, the data from the 
CAP292 backbone chimeras was given greater weight.  Thus, these data suggested 
that the V1V2 region was major target of the strain-specific neutralizing response in 
CAP292.  The partial sensitivity of the C3V4 chimeric virus suggested that low titer 




3.8  Mapping amino acid residues targeted by the broadly neutralizing 
response in CAP292 
The role of viral evolution in the development of bnAb targets has been demonstrated 
(reviewed by Moore, Williamson & Morris 150).  Viral epitopes targeted by strain specific 
neutralizing antibodies may evolve to become targets for the broadly neutralizing 
response through immune escape.  We have shown that escape from the strain-
specific responses in CAP292 occurred through insertion, deletions and glycan shift in 
the V1V2 and the C3V4 regions.  We thus aimed to map the bnAb response to assess 
the relationship between the epitopes targeted by strain specific and broadly 
neutralizing responses. 
Longitudinal SGA sequence data was generated to evaluate evolution in amino acid 
residues known to play a crucial role in neutralization by broadly neutralizing 
monoclonal antibodies.  Sites were identified as putative bnAb targets if the 
nonsynonymous mutations occurred in a known bnAb site, in more than 50% of the 
sequences at 186 w.p.i —when the broadly neutralizing response peaked.  The 
following sites were identified as putative bnAb escape sites in CAP292: L165 and 
E169 in V2; N332 in C3; a site between 463 and 464 in V5, D674 and R683 in MPER.   
In V2, an L165V mutation was first introduced at 58 w.p.i and increased in frequency 
at 186 w.p.i. (Figure 3.19).  Of the sequences at 186 w.p.i, sub-lineage 1 (blue box) 
had the wildtype L165 together with the E169K mutation while sub-lineage 2 had the 
L165V mutation.  These sites are known to be targeted by the PG9/16 class of mAbs. 
The site identified in the C3 region at position 332, is a well-known target of the 
PGT128 class of bnAbs (Figure 3.19) 113 117 151 .  The presence of the N-linked glycan 
site in the t/f sequence, and the maintenance of this site until 58 w.p.i suggests that 
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the initial antibody response (ssnAbs) did not target N332 (Figure 3.19).  However, 
two escape mutations, S334N and N336T that were introduced at 186 w.p.i resulted in 
a shift of the N-linked glycan site from 332 to 334, indicating that this site may have 
been targeted by later bnAbs.   
The shift of the N-linked glycan site from 464 to 463.1 in the V5 occurred in the CD4 
binding site.  The shift may render the sub-lineage 1 resistant to the CD4-binding 
antibodies (Figure 3.19).  The last sites identified were in MPER at positions 674 and 
683 (Figure 3.19).  The mutations occurred in a region overlapping the 4E10 and 10E8 
anti-MPER monoclonal antibodies epitopes and where found in the viral variants that 
make up sub-lineage 2 at 186 w.p.i.  This suggested MPER-like antibodies to the sub-
lineage 2 viral population. 









To identify whether any of these sites were targeted by the broad response in CAP292, 
we acquired various mutant viruses from the National Institute of Communicable 
Disease (L. Morris, National Institute of Communicable Diseases).  These included two 
constructs with alanine substitutions, representing the L165A and N332A mutants in a 
conC backbone.  The D674 construct was mutated to D674S in a Cot6 backbone.  The 
neutralization kinetics of the both the mutant viruses and the wildtype backbone viruses 
were tested against longitudinal CAP 292 plasma.  The fold difference in neutralization 
titer for the mutant and wildtype was calculated by dividing the ID50 of the wildtype virus 
by that of the mutant virus with a fold difference above one indicating an increase in 
Figure 3.19. Identifying broadly 
neutralizing antibody targets.  Amino 
acid highlighter showing sequences 
variation in putative broad neutralizing 
antibody sites in the V2, C3, V5 and gp41 
regions.  HXB2 numbering of the sites 
undergoing evolution are shown below 
the highlighter plots. Blue bars indicate 
potential N-linked glycan sites.  Sub-
lineage 1 sequences are enclosed in the 
blue box and sub-lineage 2 sequences in 
the orange box. 
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neutralization sensitivity, whereas a fold difference below one indicated a decrease in 
neutralization potential epitopes were identified as a fold increase above one indicating 
an increase in neutralization sensitivity, whereas the reduction in neutralization 
sensitivity was identified as viral escape indicated by a fold difference below one.   
The introduction of the L165A mutation resulted in increased neutralization sensitivity 
compared to wild-type conC wildtype virus at all time points over the three year time 
period (Figure 3.20).  A similar observation was made by Wibmer et al.152 where conC 
L165A was more sensitive to neutralization than the conC wildtype when tested against 
plasma of CAP257, of the CAPRISA cohort, suggesting that this mutation may change 












w.p.i 58 106 134 156 182 
conC WT 239.59 509.14 662.93 839.93 1896.7 
conC L165A 1216.31 2375.8 2372.52 2859.94 3265.58 
ID50 fold change 0.019 0.21 0.27 0.29 0.58 
Figure 3.20. Neutralization plots of the L165A mutant virus vs 
the conC wildtype.  The neutralization titers at each time point are 
shown in the table.  The ID50 fold change was calculated as the 
neutralization titer of the wildtype virus divided by that of the mutant 
virus. 






















The conC wildtype and the N332A mutant viruses had similar neutralization titers until 
the 186 w.p.i, when the broadly neutralizing antibody response peaked.  At this time 
point, the conC wildtype virus (containing the glycan site at 332) was 2.5 fold more 
sensitive to neutralization than the N332A mutant virus (Figure 3.21).  This suggested 
that the circulating antibodies required the N332 glycan for neutralization, however only 













Figure 3.21. Neutralization plots of the N332A mutant virus vs the conC 
wildtype.  The neutralization titers at each time point are shown in the table.  
The ID50 fold change was calculated as the neutralization titer of the wildtype 
virus divided by that of the mutant virus. 
 
Neutralization sensitivity assessment of the Cot6 D674S and Cot6 wildtype showed no 
significant effect on neutralization up to 182 w.p.i, with a slight reduction in 
w.p.i 58 106 134 156 182 
conC WT 239.59 509.14 662.93 839.93 1896.7 
conC N332A 101.06 330.63 662.93 674.09 765.55 
ID50 fold change 2.4 1.5 1 1.24 2.5 






















neutralization of 2.27- fold and 1.7-fold at 106 w.p.i and 182 w.p.i, respectively (Figure 
3.22).  This suggested the presence of minor neutralizing responses towards D674 












Figure 3.22. Neutralization plots of the D674S mutant virus vs the cot6 wildtype.  
The neutralization titers at each time point are shown in the table.  The ID50 fold change 
was calculated as the neutralization titer of the wildtype virus divided by that of the 
mutant virus. 
 
The reduction in neutralization that resulted from the N332A mutation, suggested that 
at least some of the bnAb response in CAP292 was directed toward the C3 region.  
Furthermore, there was some evidence of low level neutralization toward the MPER, 
given the slight reduction in neutralization due to the D674S mutation.  Together these 
w.p.i 58 106 134 156 182 
Cot6 WT 45 150.05 280.52 382.67 386.32 
Cot6 D674S 45 66.46 226.72 311.67 227.22 
ID50 fold change 1 2.27 1.2 1.227 1.7 





















data suggest that the broad neutralizing response in CAP292 may have multiple 




4 Discussion and Conclusion 
It is generally accepted that an effective HIV-1 vaccine would need to elicit broadly 
neutralizing antibodies (bnAbs) to block viral infection, and to overcome the extensive 
global HIV-1 diversity (reviewed by Stamatatos, Morris, Burton & Mascola 153).  
However, the development of such a vaccine has been elusive.  One way to get 
insights into the development of bnAbs is to elucidate how these responses evolve in 
vivo.  It is thought that pressure from the strain-specific neutralizing antibody response 
drives viral evolution towards epitopes that would later be targeted by bnAbs 154 155.  It 
is therefore of interest to understand whether the early strain-specific antibodies 
(ssnAbs) evolve into broadly neutralizing antibodies.  This study aimed to determine if 
a relationship existed between the epitopes targeted by ssnAb and bnAb in CAP292.  
We hypothesized that if ssnAbs evolved into bnAbs, they would target the same 
epitopes. 
Our data showed that the early strain-specific response targeted the V1V2 region in 
CAP292, with a C3V4 response possibly emerging at about 30 w.p.i.  The data also 
showed that the mutation acquired in the V1V2 region mediated complete escape, 
whilst those in the C3V4 mediated partial viral escape.  Viral escape occurred after 
detection of the ssnAb response resulting in viruses harvested after this time point 
being less sensitive to neutralization than the t/f virus.  Although we were unable to 
conclusively determine the targeted epitope of the broad neutralizing response, the 
bnAb mapping, together with the pattern of putative escape mutations, suggested that 
the C3 glycan (N332) and the MPER were possible targets.  Due to time constrains, 
and the confounding effect of the 165 mutation, we were not able to effectively 
interrogate the presence of V1V2 bnAb specificities.  Thus, while the V1V2 region was 
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targeted by ssnAbs, we could not confirm whether this was also the case for the later 
bnAb antibodies.   
The genetic characterisation of the env of the t/f virus provided a baseline from which 
to track evolution, and provided information on the virus that primed the immune 
response in infected individuals.  In CAP292,  consistent with infection with a single 
variant infection, we found that early sequences had a distribution of hamming 
distances that conformed to the Poisson model, with a star-like phylogeny.  There were 
however slight deviations from the model with some sequences harbouring shared 
mutations (Figure 3.4) suggesting a selective immune pressure at the time of 
sampling.   
Similar to another study by Gray et al.156, CAP292 developed potent neutralizing 
antibodies (over 1:1000, Figure 3.5) within the first year of infection, and these 
antibodies had no impact on viral replication.  Typical of HIV-1 subtype C infection, the 
specificity of the strain-specific response was mapped to the V1V2 157 158.  Mapping of 
C3V4 generated some discrepancies using different Env backbones with the C3V4 
chimera in the CAP239 backbone, showing a greater neutralization sensitivity as 
compared with the C3V4 chimera in the CAP292 backbone.  These differences are 
likely a result of differential conformations of the envelope between the two backbones 
159.  Studies have shown that higher  N-linked glycan density and longer variable loops 
are associated with neutralization resistant viruses 160 112, and the differences in these 
features  between the two backbones may have impacted the Env conformation, 
resulting in the C3V4 epitope being more accessible in the CAP239 backbone V1V2 
(Table 1).  Additionally, the mutations found in the backbones may have differing 
effects on neutralization sensitivy.  For more premise mapping of antibody targets, the 
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mutations would have to be individually tested to identify each of their contribution to 
neutralization sensitivity. 
We detected low level variation before neutralizing antibodies first emerged.  This 
could be attributed to the pressure exerted by either CTL 84, or by non-neutralizing 
antibodies.  Although it is difficult to defintively rule out CTL pressure, these mutations 
did not occur in known CTL epitopes associated with CAP292’s HLA profile (A 29:02. 
30:01; B15:03, 44:03, C 2:10, 02:10). However the variation did occur in sites in the 
V5 and gp41 regions that have been shown to evolve in response to ADCC-mediating 
antibodies 161 162 163.  However, if there was pressure from the ADCC-mediating 
antibodies, it was temporal as these variations did not persist after the emergence of 
the nAb response.  Further research would need to be conducted to determine the 
impact of the non-neutralizing antibodies on viral evolution.   
Similar to other studies, we identified the V1V2 as a major contributor to Env evolution 
and this region was shown to be a determinant of sensitivity to neutralization (Figure 
3.10).  In CAP292 the V1V2 variable loop became shorter with time, and this was 
associated with a reduction in the number of N-linked glycan sites.  Interestingly, 
viruses with the shorter V1V2 variable loops and less number of glycan sites were 
generally more resistant to neutralization, which is in contrast to the observation made 
by others 160 112.   
Interestingly, we identified two sub-lineages, at the peak of the broadly neutralizing 
response, with distinct sequence differences across V1V2, C3V4 and MPER (Figure 
3.11 & 3.12).  This pattern of viral evolution has been demonstrated 148, however 
whether this occurs as a result of two routes of escape from the same antibody 
specificity, or multiple antibodies with different specificities has not been investigated.  
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These data highlights the complexity of viral evolution leading to the development of 
the broadly neutralizing antibodies response. Identifying the neutralization sensitivity 
of each of these subpopulations in CAP292 would provide valuable insight into the 
dynamics of viral evolution in CAP292, while determining the impact of this on the bnAb 
response would be of particular interest.   
There are a number of amino acids that have been shown to be critical for bnAbs 
recogntion.  Three sites (N160, L165 and K169) have been identified as crucial for 
neutralization by PG9/16 broad neutralizing monoclonal antibodies (mAbs) 164.  In 
CAP292, we identified mutations at L165V and E169K at the peak of the broadly 
neutralizing response.  The L165V mutation occurred in sub-lineage 2 whilst the E169K 
mutation occurred in sub-lineage 1.  Contrary to our expectations, the L165A mutant 
virus was more sensitive to neutralization than the wildtype (Figure 3.19) possible due 
to the more compact structure of alanine (A), compared to lysine (K), resulting in an 
epitope being more exposed allowing easier access by the neutralizing antibodies, or 
that this change somehow affected the larger conformation of the loop, resulting 
exposing a non-neutralizing epitope.  Time constrains did not allow the interrogation of 
the E169K mutation in sub-lineage 1, which may help clarify whether a PG9/16 
specificity is present in CAP292.  However, the K (lysine) is known as the desired 
amino acid residue for PG9/16-like antibodies 165.  The reversion from E to K may 
suggest the presence of antibodies targeting the K169 in the donor drove , and that 
this kind of antibody pressure was not present in CAP292. 
CAP292 may also have developed PGT128-like antibodies.  These antibodies typically 
recognise a glycan patch which includes sites N301, N332 and N325 147.  The most 
important target of these antibodies is the glycan at position 332.  The shift of the 
glycan from N332 to N334 in CAP292 suggested the presence of PGT128-like 
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antibodies.  Our bnAb mapping data suggested that the N332A mutation resulted in an 
increase in neutralization resistance, further supporting PGT128-like specificities in 
CAP292.  The sites D674 and N671 have been shown to be crucial for neutralization 
by an anti-MPER mAb Z13e1 166.  However, neutralization sensitivity was not greatly 
impacted using the D674S mutant virus.  While these mutations occurred in sites 
confirmed as important for certain mAbs, this study was preliminary more site-directed 
mutant viruses would need to be tested to map the specificity of the broadly neutralizing 
response to single amino acids.   
 
Conclusion 
This study tracked viral evolution over three key time points during antibody 
maturation:  firstly at 14 w.p.i when the first strain-specific response emerged, followed 
by a possible second wave of antibodies to the 30_w.p.i virus, and eventually the 
development of the broad response at 58 w.p.i.  A single virus established clinical 
infection in CAP292 and there was limited evolution observed before the development 
of strain-specific neutralizing antibodies, which targeted the V1V2 region.  Antibody 
pressure to the V1V2 was maintained throughout the period of infection studied, and 
resulted in genetically diverse viral variants.   
Two viral escape pathways were established by the peak of the bnAb response.  Our 
data shows that the broad response targeted the C3 N332 glycan.  The MPER and the 
V1V2 region may have been targeted by bnAb responses, however, further work is 
required to confirm this.  If this work confirms a V1V2 bnAb target, this would provide 
good support for a relationship between early ssAb responses and later bnAb 
specificities.   
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The pathway that leads to the development of broadly neutralizing antibodies is 
dynamic and influenced by the interactions between viral and host immune factors.  
This study showed the plasticity of Env in response to the neutralizing antibody 
pressure, and that a relationship between strain specific and broad neutralizing 
epitopes may exist.  Molecular characterization of the antibody response is needed to 
determine the full extent of the antibody-virus interaction to gain insights into 














5.1 Appendix A: Primer sequences  

























FOR14 TATGGGACCAAAGCCTAAAGCCATGTG  
FOR16 TTTAATTGTGGAGGAGAATTTTTCTA  
REV15 CTGCCATTTAACAGCAGTTGAGTTGA  
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